Biotech Industry Financials, Performance and Ratios
-
Industry Score
35.2 /100
Rank 82 out of 131 Industries -
Advance/Decline
85/222
-
No. of Companies307
-
Avg. Market Cap3,173
-
Price to Earning Ratio6.68
-
Price to Earning Growth Ratio1.36
-
Price to Book Ratio14.81
-
Return on Equity12.81
-
Return on Capital Employed-
-
Return on Assets4.78
-
Dividend yield 1 year %0.24 %
-
Net Profit Growth Annual YoY %60.16 %
-
Net Profit Growth Qtr YoY %-59.79 %
-
Net Profit Growth Qtr QoQ %-2618.71 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
12,656.1
|
25.3
|
L
 -0.6%
H
25.2
26.0
|
L
 -0.8%
H
25.0
26.4
|
L
 6.0%
H
23.1
26.4
|
L
 12.8%
H
19.4
26.4
|
L
 69.7%
H
13.4
27.7
|
L
 110.8%
H
8.0
27.7
|
L
 -29.7%
H
7.9
37.5
|
L
H
7.9
37.6
|
| IQVIA |
|
33,133.0
|
198.5
|
L
 -1.5%
H
197.6
202.6
|
L
 -4.0%
H
197.6
211.9
|
L
 18.3%
H
168.8
212.4
|
L
 13.3%
H
154.5
212.4
|
L
 6.0%
H
154.5
247.0
|
L
 -13.0%
H
134.6
261.7
|
L
 -18.9%
H
134.6
285.6
|
L
 168.2%
H
70.1
285.6
|
| Nuvation Bio Inc (Class A) |
|
2,280.7
|
6.6
|
L
 1.9%
H
6.0
6.6
|
L
 11.0%
H
5.3
6.6
|
L
 13.7%
H
5.3
6.6
|
L
 27.9%
H
4.1
6.6
|
L
 178.7%
H
2.2
9.8
|
L
 242.9%
H
1.0
9.8
|
L
 -23.6%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,769.4
|
30.0
|
L
 1.7%
H
28.7
30.0
|
L
 7.0%
H
25.7
30.0
|
L
 10.1%
H
25.7
31.7
|
L
 12.6%
H
21.8
31.7
|
L
 227.2%
H
8.8
31.7
|
L
 49.6%
H
6.5
31.7
|
L
 -9.2%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
197.3
|
4.0
|
L
 2.1%
H
3.9
4.0
|
L
 3.6%
H
3.6
4.1
|
L
 -10.5%
H
3.6
4.9
|
L
 -5.7%
H
3.6
5.5
|
L
 113.4%
H
1.6
5.5
|
L
 -32.9%
H
1.2
7.2
|
L
 -87.3%
H
1.2
40.2
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,749.8
|
5.7
|
L
 -4.0%
H
5.7
6.1
|
L
 -15.0%
H
5.5
6.7
|
L
 -0.2%
H
5.5
8.4
|
L
 40.4%
H
3.8
8.4
|
L
 16.5%
H
2.7
8.4
|
L
 -27.0%
H
1.9
8.4
|
L
 -64.3%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Absci Corp |
|
1,395.9
|
8.2
|
L
 -1.0%
H
8.1
8.5
|
L
 -15.6%
H
7.6
9.6
|
L
 -1.9%
H
7.4
12.1
|
L
 123.9%
H
3.6
12.1
|
L
 127%
H
2.2
12.1
|
L
 241.9%
H
1.1
12.1
|
L
 -61.8%
H
1.1
31.5
|
L
H
1.1
31.5
|
| Adma Biologics Inc |
|
1,942.3
|
8.4
|
L
 -2.4%
H
8.3
8.7
|
L
 -3.5%
H
8.3
8.9
|
L
 -2.2%
H
8.2
9.3
|
L
 -23.5%
H
7.5
11.4
|
L
 -50.9%
H
7.2
20.5
|
L
 119.4%
H
3.1
25.7
|
L
 430.4%
H
1.0
25.7
|
L
 25.1%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
3,513.0
|
22.0
|
L
 -2.8%
H
21.5
22.7
|
L
 -4.2%
H
20.9
23.2
|
L
 -68.4%
H
20.9
91.2
|
L
 -61.4%
H
20.9
91.2
|
L
 -47.9%
H
20.9
91.2
|
L
 -32.1%
H
9.1
91.2
|
L
 -85.4%
H
9.1
160
|
L
H
9.1
285
|
| Agenus Inc |
|
230.3
|
5.5
|
L
 -0.9%
H
5.5
5.9
|
L
 10.4%
H
4.7
5.9
|
L
 81.9%
H
2.9
8.7
|
L
 40.4%
H
2.9
8.7
|
L
 -9.6%
H
2.7
8.7
|
L
 -82.9%
H
1.4
196
|
L
 -95.0%
H
1.4
196
|
L
 -94.1%
H
1.4
196
|
| Change Agents Corp |
|
3.5
|
0.3
|
L
 -3.6%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 -25%
H
0.2
0.4
|
L
 -35.7%
H
0.2
0.4
|
L
 -88.8%
H
0.2
4.7
|
L
 -81.4%
H
0.2
11.7
|
L
 -97.0%
H
0.2
11.9
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
102.5
|
1.7
|
L
 -2.9%
H
1.7
1.8
|
L
 -11.5%
H
1.6
1.9
|
L
 -17.1%
H
1.6
2.5
|
L
H
1.5
2.5
|
L
 -68.3%
H
1.1
6.2
|
L
 -78.7%
H
1.1
8.4
|
L
 -81.5%
H
1.1
12.0
|
L
 -70.8%
H
1.1
16.7
|
| Alector Inc |
|
169.9
|
1.5
|
L
 -0.7%
H
1.5
1.5
|
L
 2%
H
1.4
1.6
|
L
 -14.0%
H
1.4
2.1
|
L
 -37.6%
H
1.4
2.7
|
L
 -11.1%
H
1.1
3.4
|
L
 -77.1%
H
0.9
9.1
|
L
 -95.2%
H
0.9
35.1
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
642.0
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 -2.1%
H
1.7
1.9
|
L
 -11.4%
H
1.7
2.3
|
L
 -22.2%
H
1.7
2.4
|
L
 31.0%
H
1.0
4.5
|
L
 -65.6%
H
0.9
5.8
|
L
 -91.6%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
546.5
|
2.8
|
L
 -0.4%
H
2.8
2.9
|
L
 -5.7%
H
2.8
3.0
|
L
 -4.1%
H
2.7
3.4
|
L
 -19.0%
H
2.6
3.4
|
L
 -33.1%
H
2.6
6.4
|
L
 -10.5%
H
2.1
14.8
|
L
 -69.6%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,078.9
|
3.2
|
L
 -9.4%
H
3.2
3.5
|
L
 -5.6%
H
3.2
3.6
|
L
 -12.6%
H
3.2
4.0
|
L
 -8.9%
H
2.9
4.6
|
L
 -63.3%
H
2.9
9.9
|
L
 -67.8%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
96.8
|
4.1
|
L
 0.7%
H
3.9
4.1
|
L
 -15.6%
H
3.5
6.3
|
L
 -7.5%
H
3.5
6.3
|
L
 -35.7%
H
3.5
6.5
|
L
 58.4%
H
2.1
11.9
|
L
 14.3%
H
0.4
12.9
|
L
 -77.4%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
271.8
|
2.0
|
L
 -1.5%
H
2.0
2.0
|
L
 -0.5%
H
1.9
2.2
|
L
 23.9%
H
1.6
2.4
|
L
 18.8%
H
1.4
2.4
|
L
 320.8%
H
0.5
2.7
|
L
 -70.0%
H
0.4
17.8
|
L
 -96.6%
H
0.4
81.2
|
L
H
0.4
117.5
|
| Amgen |
|
197,560.2
|
366.1
|
L
 -0.1%
H
364.9
371
|
L
 2.2%
H
357.7
378.5
|
L
 6.2%
H
345.5
378.5
|
L
 5.8%
H
320.5
378.5
|
L
 19.8%
H
269.8
391.3
|
L
 55.9%
H
228.2
391.3
|
L
 49.6%
H
198.6
391.3
|
L
 121.0%
H
133.6
391.3
|
| AnaptysBio Inc |
|
1,557.7
|
52.6
|
L
 -2.1%
H
52.3
54
|
L
 -5.8%
H
49.7
59.1
|
L
 -12.3%
H
49.7
70.9
|
L
 -1.8%
H
49.7
72.4
|
L
 100.7%
H
17.1
73.3
|
L
 190.3%
H
12.2
73.3
|
L
 103.8%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,764.4
|
77.6
|
L
 -2.0%
H
77.3
80.0
|
L
 -4.0%
H
77.0
83.0
|
L
 -3.7%
H
77.0
87.2
|
L
 -3.2%
H
73.5
87.8
|
L
 17.0%
H
62.6
99.5
|
L
 48.7%
H
48.2
99.5
|
L
 133.3%
H
22.3
99.5
|
L
 32.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
119.8
|
3.5
|
L
 -1.1%
H
3.4
3.7
|
L
 0.6%
H
3.3
3.7
|
L
 27.1%
H
2.4
3.7
|
L
 12.1%
H
2.3
3.7
|
L
 5.4%
H
2.3
5.5
|
L
 -4.9%
H
2.1
5.5
|
L
 -19.1%
H
2.1
6.5
|
L
 2.0%
H
0.6
8.1
|
| Aptevo Therapeutics Inc |
|
5.5
|
4.5
|
L
 0.7%
H
4.4
4.5
|
L
 -2.6%
H
4.3
4.9
|
L
 -6.3%
H
3.7
4.9
|
L
 -13.3%
H
3.7
5.6
|
L
 -92.1%
H
3.7
59.4
|
L
 -100.0%
H
3.7
668131.2
|
L
 -100.0%
H
3.7
12940587.7
|
L
 -100.0%
H
3.7
68020444.8
|
| AquaBounty Tech Inc |
|
4.8
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 -5.1%
H
0.9
1.0
|
L
 -6.9%
H
0.9
1.3
|
L
 -3.1%
H
0.9
1.3
|
L
 20.5%
H
0.7
3.0
|
L
 -88.4%
H
0.5
8.2
|
L
 -99.1%
H
0.5
106.1
|
L
H
0.5
610
|
| Arvinas Inc |
|
532.9
|
8.3
|
L
H
8.2
8.4
|
L
 -0.2%
H
7.9
8.4
|
L
 6.7%
H
7.6
8.9
|
L
 -22.3%
H
7.0
11.4
|
L
 9.0%
H
6.1
14.5
|
L
 -65.5%
H
5.9
53.1
|
L
 -90.2%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
12,494.0
|
88.7
|
L
 19.0%
H
84.3
95.5
|
L
 23.5%
H
70.0
95.5
|
L
 8.2%
H
69.9
95.5
|
L
 20.0%
H
69.0
95.5
|
L
 492.9%
H
15.0
95.5
|
L
 145.8%
H
9.6
95.5
|
L
 30.6%
H
9.6
95.5
|
L
 1469.9%
H
1.2
95.5
|
| LeonaBio Inc |
|
71.0
|
7.6
|
L
 -5.3%
H
7.6
8
|
L
 -11.4%
H
7
8.8
|
L
 -8.6%
H
7
10.1
|
L
 -17.5%
H
7
11.4
|
L
 61.9%
H
3.2
14.2
|
L
 -76.1%
H
2.2
43.0
|
L
 -92.8%
H
2.2
166.5
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
1,971.5
|
15.3
|
L
 -2.0%
H
15.3
15.7
|
L
 -4.8%
H
15.2
16.2
|
L
 -12.6%
H
15.2
19.3
|
L
 -6.6%
H
14.4
19.3
|
L
 72.6%
H
8.8
19.3
|
L
 40.1%
H
4.7
19.3
|
L
 32.5%
H
4.1
34.0
|
L
 405.9%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
725.1
|
7.0
|
L
 -0.3%
H
6.9
7.1
|
L
H
6.7
7.1
|
L
 0.9%
H
6.5
7.9
|
L
 -6.4%
H
6.0
9.5
|
L
 3.6%
H
4.7
9.5
|
L
 -40.6%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
596.1
|
31.6
|
L
 -3.7%
H
31.4
32.6
|
L
 -2.8%
H
30.2
33.4
|
L
 4.1%
H
29.5
39.5
|
L
 10.8%
H
26.3
39.5
|
L
 42.2%
H
14.4
39.5
|
L
 79.1%
H
1.4
61.1
|
L
 -66.1%
H
1.4
97.2
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,208.1
|
19.9
|
L
 -3.3%
H
19.6
20.5
|
L
 -9.2%
H
19.3
22.3
|
L
 2.1%
H
19
23.5
|
L
 -21.8%
H
14.3
28
|
L
 121.1%
H
6.7
28
|
L
 -96.7%
H
6.6
1134.5
|
L
 -96.0%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
236.3
|
2.6
|
L
 -0.4%
H
2.5
2.6
|
L
 2%
H
2.3
2.6
|
L
 0.4%
H
2.3
2.8
|
L
 -29.4%
H
2.3
3.6
|
L
 -77.2%
H
2.3
14.0
|
L
 -68.6%
H
2.3
14.4
|
L
 -88.6%
H
2.3
23.7
|
L
 -62.8%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
12,330.8
|
239.6
|
L
 1.1%
H
233.7
240.7
|
L
 0.9%
H
221.2
240.9
|
L
 -3.3%
H
221.2
252.6
|
L
 28.5%
H
180
260.2
|
L
 133.7%
H
96.1
260.2
|
L
 218.9%
H
55.0
260.2
|
L
 328.8%
H
19.4
260.2
|
L
 2987.9%
H
1.9
260.2
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 -3.1%
H
0.9
1
|
L
 -7%
H
0.9
1.1
|
L
 -19.1%
H
0.9
1.3
|
L
 -55.7%
H
0.5
2.4
|
L
 -61.4%
H
0.5
2.6
|
L
 -88.7%
H
0.5
9.8
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
17.2
|
9.8
|
L
 5.5%
H
8.7
10.1
|
L
 -18.7%
H
8.7
12.5
|
L
 -12.6%
H
8.7
15.5
|
L
 69.4%
H
3.0
29.3
|
L
 -78.3%
H
3.0
49.6
|
L
 -92.9%
H
3.0
219.8
|
L
 -99.3%
H
3.0
1504
|
L
 -99.9%
H
3.0
17759.8
|
| Argen X SE (ADR) |
|
53,284.4
|
851.7
|
L
 -2.6%
H
850.0
874.6
|
L
 -1.3%
H
843.6
877.6
|
L
 -5.8%
H
837.7
953.6
|
L
 7.4%
H
754.8
953.6
|
L
 49.1%
H
566.4
953.6
|
L
 55.3%
H
327.7
953.6
|
L
 169.0%
H
249.5
953.6
|
L
H
17.3
953.6
|
| BridgeBio Pharma Inc |
|
16,189.9
|
82.7
|
L
 0.3%
H
81.0
82.9
|
L
H
79.0
83.2
|
L
 19.9%
H
68.0
93.4
|
L
 11.0%
H
62.5
93.4
|
L
 80.6%
H
42.1
93.4
|
L
 142.2%
H
21.6
93.4
|
L
 34.1%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioAtla Inc |
|
5.6
|
3.4
|
L
 -8.1%
H
3.3
3.7
|
L
 -20.4%
H
3.3
4.3
|
L
 -6.4%
H
3.3
4.7
|
L
 -42.0%
H
3.1
5.8
|
L
 -80.1%
H
3.1
71.5
|
L
 -97.7%
H
3.1
201
|
L
 -99.8%
H
3.1
2186.5
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
13.5
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 3.4%
H
0.8
0.9
|
L
 -6.2%
H
0.8
1.3
|
L
 -24.2%
H
0.8
1.8
|
L
 -60.4%
H
0.8
2.4
|
L
 -96.9%
H
0.8
23.3
|
L
 -98.3%
H
0.8
59.4
|
L
 -99.6%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,417.1
|
9.5
|
L
 1.0%
H
9.4
9.7
|
L
 1.1%
H
9.0
9.7
|
L
 4.1%
H
9.0
11.2
|
L
 5.6%
H
7.8
11.2
|
L
 9.9%
H
6
11.2
|
L
 27.3%
H
4.0
11.3
|
L
 -44.0%
H
4.0
20.0
|
L
 208.8%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
31.3
|
3.6
|
L
 -4%
H
3.5
3.7
|
L
 -8.6%
H
3.5
3.9
|
L
 19.6%
H
2.9
4
|
L
 -7.9%
H
2.6
4.3
|
L
 -95.5%
H
2.6
83.9
|
L
 -100.0%
H
2.6
11275.5
|
L
 -99.9%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
83250
|
| Black Diamond Therapeutics Inc |
|
104.9
|
1.8
|
L
 -2.1%
H
1.8
1.9
|
L
 1.1%
H
1.8
1.9
|
L
 13.7%
H
1.6
2.2
|
L
 -45.4%
H
1.6
4.0
|
L
 -42.6%
H
1.6
4.9
|
L
 -59.3%
H
1.2
7.7
|
L
 -81.5%
H
1.2
10.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,740.7
|
26.6
|
L
 -2.4%
H
26.5
27.2
|
L
 -13.6%
H
26.1
30.3
|
L
 -25.0%
H
26.1
38.3
|
L
 -15.9%
H
25.9
38.3
|
L
 23.7%
H
15.6
38.3
|
L
 -16.9%
H
13.5
49.5
|
L
 -72.0%
H
13.5
116.9
|
L
H
13
138.5
|
| BioVie Inc |
|
10.1
|
1.3
|
L
 3.9%
H
1.3
1.4
|
L
 -24.3%
H
1.3
1.8
|
L
 -30.9%
H
1.3
2.3
|
L
 -14.1%
H
1.3
2.3
|
L
 -83.6%
H
1.1
8.4
|
L
 -99.7%
H
1.1
582
|
L
 -99.9%
H
1.1
1595.5
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
11,287.8
|
58.4
|
L
 -1.4%
H
58.3
60.0
|
L
 -0.9%
H
58.3
60.6
|
L
 4.5%
H
55.7
60.7
|
L
 7.9%
H
49.3
60.7
|
L
 -1.4%
H
49.3
66.3
|
L
 -33.4%
H
49.3
99.6
|
L
 -25.6%
H
49.3
117.8
|
L
 -37.6%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
12.9
|
1.1
|
L
H
1.1
1.1
|
L
 -5.9%
H
1.1
1.2
|
L
 -2.6%
H
1.1
1.2
|
L
 -10.4%
H
1.1
1.4
|
L
 -68.3%
H
1.1
5.5
|
L
 -81.2%
H
0.1
11.6
|
L
 -98.2%
H
0.1
63.7
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
393.0
|
11.4
|
L
 -3.8%
H
11.3
11.9
|
L
 -12.1%
H
11.3
13.3
|
L
 -7.0%
H
11.3
14.3
|
L
 -11.7%
H
10
14.3
|
L
 1.6%
H
9.9
16.8
|
L
 208.4%
H
1.9
17.2
|
L
 -82.7%
H
1.9
81.3
|
L
 -97.5%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
9.8
|
1.2
|
L
 3.5%
H
1.2
1.2
|
L
 1.7%
H
1.1
1.2
|
L
 -0.8%
H
1.1
1.3
|
L
 -9.1%
H
1.1
1.5
|
L
 -16.7%
H
1.1
3.4
|
L
 -99.3%
H
1.1
180
|
L
 -100.0%
H
1.1
3775
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
27.2
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 -4.4%
H
0.8
0.9
|
L
 -32.3%
H
0.7
1.5
|
L
 -23.5%
H
0.7
1.5
|
L
 -51.1%
H
0.7
8.1
|
L
 -92.1%
H
0.2
11.2
|
L
 -96.6%
H
0.2
36.5
|
L
H
0.2
71.5
|
| BioNTech SE (ADR) |
|
23,222.4
|
91.8
|
L
 -0.5%
H
91.6
93.2
|
L
 -0.2%
H
90.6
93.9
|
L
 1.8%
H
88.4
98.8
|
L
 -15.4%
H
85.0
109.8
|
L
 -17.6%
H
79.5
124
|
L
 -15.4%
H
76.5
131.5
|
L
 -67.3%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
448.4
|
2.8
|
L
 -2.5%
H
2.7
2.8
|
L
 -0.7%
H
2.6
2.9
|
L
 -8.6%
H
2.6
3.3
|
L
 -13.3%
H
2.6
4.2
|
L
 74.1%
H
1.3
4.2
|
L
 -79.6%
H
1.0
26.4
|
L
 -66.5%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
739.3
|
10.1
|
L
 -1.3%
H
10.0
10.3
|
L
 4.7%
H
9.2
10.6
|
L
 10.3%
H
9.0
11.4
|
L
 37.5%
H
6.1
11.4
|
L
 51.3%
H
4.4
11.4
|
L
 707.2%
H
0.7
14.6
|
L
H
0.7
14.8
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
11.7
|
0.7
|
L
 4.2%
H
0.7
0.8
|
L
 -5.1%
H
0.7
0.8
|
L
 -5.1%
H
0.5
1.2
|
L
 21.3%
H
0.5
1.2
|
L
 -80.4%
H
0.5
7.2
|
L
 -80.1%
H
0.5
8.4
|
L
 -98.8%
H
0.5
63
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
25.9
|
2.8
|
L
 -3.5%
H
2.7
2.9
|
L
 -5.8%
H
2.7
3.5
|
L
 3.0%
H
1.5
5.7
|
L
 -14.6%
H
1.5
5.7
|
L
 -89.1%
H
1.5
43.7
|
L
 -97.4%
H
1.5
124.2
|
L
 -99.4%
H
1.5
681.5
|
L
 -98.7%
H
1.5
1067.3
|
| C4 Therapeutics Inc |
|
413.5
|
3.7
|
L
 -2.4%
H
3.6
4.0
|
L
 -1.6%
H
3.4
4.0
|
L
 -9.2%
H
3.4
5.2
|
L
 21.8%
H
2.5
5.2
|
L
 68.5%
H
1.7
5.2
|
L
 0.5%
H
1.1
11.9
|
L
 -90.7%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
228.9
|
2.4
|
L
 -2.8%
H
2.4
2.5
|
L
 2.5%
H
2.3
2.5
|
L
 16.9%
H
2.0
2.6
|
L
 -14.5%
H
2.0
3.2
|
L
 56.1%
H
1.3
3.2
|
L
 103.4%
H
0.5
3.2
|
L
 -64.3%
H
0.5
7.5
|
L
 -63.3%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
85.9
|
1.0
|
L
 -4%
H
1.0
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 -42.9%
H
0.9
1.8
|
L
 -25.6%
H
0.9
1.8
|
L
 23.1%
H
0.6
3.8
|
L
 -49.2%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Celldex Therapeutics Inc |
|
2,729.2
|
34.8
|
L
 -2.5%
H
33.4
36.1
|
L
 -9.2%
H
33.4
37.9
|
L
 4.1%
H
32.6
40.3
|
L
 1.6%
H
28.4
40.3
|
L
 55.5%
H
19.7
40.3
|
L
 -4.5%
H
14.4
53.2
|
L
 -21.6%
H
14.4
57.2
|
L
 -51.1%
H
1.5
75.3
|
| Co-Diagnostics Inc |
|
8.4
|
2.3
|
L
 -3.4%
H
2.3
2.6
|
L
 -8.4%
H
2.2
2.6
|
L
 -26.9%
H
2.2
4.6
|
L
 34.9%
H
1.3
13.5
|
L
 -74.2%
H
1.3
46.5
|
L
 -95.9%
H
1.3
66.9
|
L
 -99.3%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
262.6
|
5.0
|
L
 -6.6%
H
4.9
5.3
|
L
 -3.7%
H
4.3
5.6
|
L
 -66.2%
H
4.3
14.5
|
L
 -67.0%
H
4.3
18.8
|
L
 -54.4%
H
4.3
21.4
|
L
 -80.4%
H
2.3
27.6
|
L
 -49.4%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
6,756.1
|
39.5
|
L
 -0.3%
H
38.8
40.2
|
L
 0.6%
H
37.1
40.2
|
L
 10.3%
H
34.7
40.9
|
L
 8.7%
H
30.9
40.9
|
L
 217.6%
H
10.4
43.7
|
L
 223.8%
H
3.7
43.7
|
L
 492.8%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Coya Therapeutics Inc |
|
102.5
|
4.4
|
L
 -4.0%
H
4.3
4.6
|
L
 -9.7%
H
4.3
4.9
|
L
 -17.4%
H
4.3
6.2
|
L
 -0.9%
H
3.9
6.2
|
L
 -23.2%
H
3.7
7.8
|
L
 9.8%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Caribou Biosciences Inc |
|
164.6
|
1.7
|
L
 0.6%
H
1.6
1.7
|
L
 -4.1%
H
1.6
1.7
|
L
 1.2%
H
1.6
2.1
|
L
 -29.7%
H
1.6
2.5
|
L
 -30.0%
H
1.4
3.5
|
L
 -74.9%
H
0.7
8.3
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
147.5
|
1.3
|
L
 3.2%
H
1.2
1.3
|
L
 15.3%
H
1.1
1.3
|
L
 20.8%
H
1.0
1.3
|
L
 -15.2%
H
1.0
1.5
|
L
 -8.6%
H
0.9
1.7
|
L
 45.5%
H
0.7
3.1
|
L
 -53.6%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
9.6
|
4.9
|
L
 4%
H
4.7
5.5
|
L
 4.4%
H
4.4
5.5
|
L
 -42.3%
H
3.6
11.4
|
L
 -59.8%
H
3.6
12.8
|
L
 -86.4%
H
3.6
39
|
L
 -98.5%
H
3.6
349.8
|
L
 -99.8%
H
3.6
3616
|
L
 -99.8%
H
3.6
7440
|
| CorMedix Inc |
|
622.9
|
7.9
|
L
 -3.1%
H
7.9
8.2
|
L
 -5.7%
H
7.7
8.5
|
L
 -10.0%
H
7.5
9.0
|
L
 6.0%
H
7.3
9.1
|
L
 -28.2%
H
6.1
15.0
|
L
 103.6%
H
2.6
17.4
|
L
 23.7%
H
2.6
17.4
|
L
 3.1%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
4,652.4
|
47.2
|
L
 -1.9%
H
46.7
48.1
|
L
 -8.0%
H
46.7
50.8
|
L
 -13.1%
H
46.7
63.5
|
L
 -16.3%
H
46.7
63.5
|
L
 -28.4%
H
44.1
78.5
|
L
 -16.7%
H
30.0
91.1
|
L
 -62.1%
H
30.0
142.6
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
85.1
|
6.1
|
L
 0.5%
H
6.0
6.2
|
L
 6.1%
H
5.7
6.2
|
L
 -1.9%
H
5.6
6.7
|
L
 2%
H
5.6
7
|
L
 -21.8%
H
5.5
8.7
|
L
 -12.1%
H
3.6
12.0
|
L
 -40.6%
H
3.6
12.0
|
L
 203.5%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
143.7
|
34.2
|
L
 2.2%
H
32.9
35.6
|
L
 20.0%
H
25.7
35.6
|
L
 11.3%
H
24.6
45.5
|
L
 96.6%
H
10.8
45.5
|
L
 26.8%
H
5.0
45.5
|
L
 -72.9%
H
5.0
131.3
|
L
 -89.1%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
6.5
|
2.1
|
L
 -3.2%
H
2.1
2.2
|
L
 -10.6%
H
2.1
2.6
|
L
 -34.0%
H
2.1
3.9
|
L
 -64.2%
H
2.1
7.3
|
L
 -80.6%
H
2.1
14.6
|
L
 75%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
10.5
|
1.4
|
L
 -2.7%
H
1.4
1.5
|
L
 -5.9%
H
1.4
1.6
|
L
 -5.3%
H
1.4
2.8
|
L
 -15.4%
H
1.4
2.8
|
L
 -68.1%
H
1.4
4.8
|
L
 -73.5%
H
1.4
10.2
|
L
 -98.0%
H
1.4
74.0
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,609.9
|
11.9
|
L
 -2.1%
H
11.9
12.2
|
L
 -10.4%
H
11.5
14.6
|
L
 -5.5%
H
11.5
15.4
|
L
 36.3%
H
8.2
15.4
|
L
 169.9%
H
3.9
15.4
|
L
 33.1%
H
2.3
15.4
|
L
 -67.7%
H
2.3
49.5
|
L
H
2.3
61.7
|
| DiaMedica Therapeutics Inc |
|
374.0
|
6.9
|
L
 -2.0%
H
6.9
7.1
|
L
 -9.2%
H
6.6
7.6
|
L
 17.8%
H
5.8
8.5
|
L
 7.3%
H
5.2
8.5
|
L
 50.9%
H
4.0
10.4
|
L
 92.2%
H
1.9
10.4
|
L
 81.2%
H
1.1
10.4
|
L
 45.2%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,751.9
|
23.6
|
L
 -0.8%
H
23.4
24.1
|
L
 2.7%
H
22.0
24.1
|
L
 -1.7%
H
22.0
27.3
|
L
 16.7%
H
17.7
27.3
|
L
 70.4%
H
12.6
27.3
|
L
 -18.9%
H
10.6
33.3
|
L
 -63.4%
H
10.6
65.3
|
L
H
10.6
93.9
|
| Bright Minds Biosciences Inc |
|
740.4
|
75.5
|
L
 -2.4%
H
75.0
77.0
|
L
 -0.6%
H
73
79.2
|
L
 18.9%
H
63
79.2
|
L
 -16.3%
H
56.5
92
|
L
 185.6%
H
26.7
123.8
|
L
 2126.0%
H
0.9
123.8
|
L
 249.4%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
735.7
|
11.8
|
L
 -2.3%
H
11.7
12.1
|
L
 -12.9%
H
11.7
14.2
|
L
 -14.0%
H
11.7
15.9
|
L
 -11.9%
H
9.9
17.3
|
L
 177.2%
H
3.8
17.3
|
L
 60.1%
H
1.9
17.3
|
L
 -33.3%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
188.9
|
7.3
|
L
 -3.9%
H
7.2
7.6
|
L
 -16.9%
H
7.2
8.8
|
L
 3.4%
H
6.6
9.6
|
L
 -7.5%
H
6
9.6
|
L
 50.6%
H
3.5
9.6
|
L
 1043.8%
H
0.3
19.4
|
L
 -30.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,836.9
|
23.2
|
L
 -2.6%
H
21.7
23.4
|
L
 -3.3%
H
21.3
24.8
|
L
 11.2%
H
20.2
24.8
|
L
 18%
H
15.9
24.8
|
L
 152.0%
H
8.9
25
|
L
 113.5%
H
6.4
47.5
|
L
 21.4%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
426.6
|
2.8
|
L
 -3.8%
H
2.7
2.9
|
L
 -8.6%
H
2.7
3.1
|
L
 -0.7%
H
2.6
3.8
|
L
 -16.5%
H
2.4
3.9
|
L
 -17.3%
H
1.7
4.5
|
L
 -68.9%
H
0.9
11.7
|
L
 -93.5%
H
0.9
73.0
|
L
 -89.7%
H
0.9
100.0
|
| Eloxx Pharma |
|
42.9
|
12.5
|
L
 3.9%
H
11.4
12.7
|
L
 -1.0%
H
11.1
14.3
|
L
 -10.2%
H
10
15
|
L
 206.4%
H
8.2
17.5
|
L
 206.4%
H
8.2
17.5
|
L
 89.8%
H
0
17.5
|
L
 -78.6%
H
0
75.6
|
L
 -91.3%
H
0
984
|
| Elicio Therapeutics Inc |
|
81.9
|
3.1
|
L
 1.3%
H
3.0
3.2
|
L
 2.6%
H
3.0
3.4
|
L
 -24.6%
H
2.8
5.4
|
L
 -74.0%
H
2.7
16
|
L
 -66.5%
H
2.7
16
|
L
 -68.6%
H
2.7
16
|
L
 -97.2%
H
2.7
141.8
|
L
H
2.7
263
|
| Enliven Therapeutics Inc |
|
3,775.5
|
52.9
|
L
 -2.7%
H
52.8
54.3
|
L
 -0.6%
H
49.6
54.9
|
L
 15.0%
H
45.0
54.9
|
L
 18.9%
H
33.5
54.9
|
L
 145.1%
H
14.8
54.9
|
L
 174.8%
H
9.8
54.9
|
L
 135.5%
H
3.9
54.9
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
720.4
|
12.6
|
L
 -4.0%
H
12.4
13.2
|
L
 -9.3%
H
12.0
13.8
|
L
 3.3%
H
11.9
14.4
|
L
 35.3%
H
7.9
14.4
|
L
 792.2%
H
1.4
14.4
|
L
 360.8%
H
1.1
14.4
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
77.1
|
4.6
|
L
 -3.2%
H
4.5
4.8
|
L
 -21.6%
H
4.3
5.9
|
L
 638.7%
H
0.4
7.6
|
L
 414.6%
H
0.4
7.6
|
L
 288.1%
H
0.4
7.6
|
L
 86.2%
H
0.4
7.6
|
L
 -40.4%
H
0.4
14.0
|
L
 -93.0%
H
0.4
81.6
|
| Enochian Biosciences Inc |
|
-
|
2.6
|
L
 -5.4%
H
2.6
2.8
|
L
 -12.4%
H
2.6
3.1
|
L
 -37.1%
H
2.6
4.8
|
L
 715.6%
H
0.2
5.0
|
L
 741.9%
H
0.1
5.0
|
L
 383.3%
H
0.1
5.0
|
L
 -47.6%
H
0.1
13.8
|
L
 30.5%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
4.3
|
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 3.7%
H
0.2
0.3
|
L
 -34.9%
H
0.2
0.4
|
L
 -87.3%
H
0.2
2.8
|
L
 -86.7%
H
0.1
9.9
|
L
 -100.0%
H
0.1
1737.6
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
174.5
|
2.8
|
L
 4.9%
H
2.5
2.8
|
L
 5.3%
H
2.4
2.8
|
L
 -3.5%
H
2.4
3.5
|
L
 18.5%
H
1.8
3.5
|
L
 607.7%
H
0.4
3.5
|
L
 236.6%
H
0.3
3.5
|
L
 -51.0%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Evogene Ltd |
|
6.5
|
0.5
|
L
 1.9%
H
0.5
0.6
|
L
 -6.9%
H
0.5
0.7
|
L
 8%
H
0.4
0.7
|
L
 -33.3%
H
0.4
0.9
|
L
 -58.5%
H
0.4
1.5
|
L
 -95.2%
H
0.4
11.2
|
L
 -98.2%
H
0.4
35.8
|
L
 -99.1%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,124.0
|
38.3
|
L
 -3.2%
H
38.3
39.8
|
L
 -6.1%
H
37.3
40.7
|
L
 5.0%
H
36.0
48.4
|
L
 19.2%
H
30.1
48.4
|
L
 183.1%
H
12.3
48.4
|
L
 398.4%
H
5.1
48.4
|
L
 87.0%
H
5.1
48.4
|
L
H
5.1
48.4
|
| Evaxion Biotech A/S (ADR) |
|
25.4
|
3.0
|
L
 0.7%
H
3.0
3.1
|
L
 -0.3%
H
2.9
3.3
|
L
 -11.1%
H
2.9
3.6
|
L
 -28.8%
H
2.9
4.8
|
L
 16.5%
H
2.5
12.2
|
L
 -75.5%
H
0.8
13.8
|
L
 -94.9%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
300.7
|
2.6
|
L
 -8.8%
H
2.6
2.8
|
L
 -13.7%
H
2.6
2.9
|
L
 20%
H
1.8
3.2
|
L
 88.3%
H
1.2
3.2
|
L
 108.1%
H
0.9
3.2
|
L
 -42.2%
H
0.7
8.8
|
L
 -97.0%
H
0.7
97.4
|
L
 51.8%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
1,159.7
|
56.6
|
L
 11.6%
H
48.6
56.8
|
L
 28.3%
H
40.7
56.8
|
L
 209.8%
H
16.9
56.8
|
L
 89.8%
H
15.5
56.8
|
L
 443.0%
H
9.1
56.8
|
L
 126.5%
H
4.1
56.8
|
L
 -93.1%
H
4.1
828.5
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
572.9
|
11.0
|
L
 -3.7%
H
10.9
11.4
|
L
 -6.2%
H
10.3
12.0
|
L
 5.2%
H
10.2
14
|
L
 11.8%
H
8.1
14
|
L
 143.6%
H
4.3
14
|
L
 -39.2%
H
2.2
36.3
|
L
 -55.2%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
358.5
|
10.3
|
L
 -0.7%
H
10.2
10.4
|
L
 -2.6%
H
9.8
10.8
|
L
 8.3%
H
9.3
11.3
|
L
 54.5%
H
6.1
11.3
|
L
 20.4%
H
5.7
11.3
|
L
 25.9%
H
4.0
11.9
|
L
 53.8%
H
3.8
11.9
|
L
 391.4%
H
1.6
15.0
|
| Foghorn Therapeutics Inc |
|
305.9
|
5.2
|
L
 1.0%
H
5.1
5.2
|
L
 -4.4%
H
4.9
5.4
|
L
 24.6%
H
4.0
6.6
|
L
 -3.3%
H
3.5
6.6
|
L
 -17.8%
H
3.3
7.0
|
L
 -35.7%
H
2.7
10.2
|
L
 -46.1%
H
2.7
24.3
|
L
H
2.7
28.3
|
| First Wave BioPharma Inc |
|
5.3
|
3.4
|
L
 -3.4%
H
3.3
3.6
|
L
 -15.6%
H
3.2
4.1
|
L
 -29.6%
H
3.2
5.1
|
L
 45.5%
H
2.1
6.9
|
L
 584%
H
0.4
6.9
|
L
 -73.2%
H
0.4
22.2
|
L
 -100.0%
H
0.4
35991.6
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
230.5
|
3.5
|
L
 -8.9%
H
3.5
3.9
|
L
 -26.5%
H
3.5
4.7
|
L
 25%
H
2.7
5.6
|
L
 42.9%
H
2.0
5.6
|
L
 22.4%
H
2.0
7.1
|
L
 114.7%
H
0.7
7.1
|
L
 27.3%
H
0.7
7.1
|
L
 133.3%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
78.5
|
1.8
|
L
H
1.8
1.9
|
L
 9.5%
H
1.6
1.9
|
L
 -0.5%
H
1.6
2.2
|
L
 -9.8%
H
1.5
2.2
|
L
 13.6%
H
1.4
4.3
|
L
 -57.2%
H
0.9
5.3
|
L
 -79.9%
H
0.9
9.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
11.4
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -5.9%
H
0.9
1.0
|
L
 -11.1%
H
0.9
1.2
|
L
 -4%
H
0.7
1.4
|
L
 -52.5%
H
0.7
3.7
|
L
 -74.4%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
904.5
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -0.7%
H
1.4
1.5
|
L
 5.2%
H
1.3
1.6
|
L
 -9.0%
H
1.1
1.7
|
L
 10.2%
H
1.0
2.0
|
L
 -54.1%
H
1.0
5.3
|
L
 9.3%
H
1.0
5.3
|
L
 -47.0%
H
0.8
7.0
|
| Gilead Sciences |
|
161,826.2
|
130.3
|
L
 0.1%
H
130.2
132.9
|
L
 -1.0%
H
129.1
140.6
|
L
 4.4%
H
123.7
140.6
|
L
 -1.9%
H
121.4
140.6
|
L
 18.3%
H
108.5
157.3
|
L
 61.6%
H
62.1
157.3
|
L
 89.9%
H
57.2
157.3
|
L
 50.6%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
194.8
|
13.3
|
L
 -9.4%
H
13
14.8
|
L
 -32.1%
H
13
21.7
|
L
 -44.1%
H
13
24.6
|
L
 -46.8%
H
13
29.9
|
L
 19.1%
H
7.8
34.1
|
L
 45.8%
H
7.6
34.1
|
L
 -69.5%
H
6.8
48.5
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
2,009.8
|
23.8
|
L
 0.7%
H
23.1
23.8
|
L
 1.6%
H
22.1
25.2
|
L
 27.4%
H
18.4
25.2
|
L
 13.4%
H
16.1
25.2
|
L
 320.3%
H
4.1
25.8
|
L
 238.9%
H
2.4
25.8
|
L
 7.4%
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
4.9
|
0.9
|
L
 -6%
H
0.9
1.0
|
L
 -6.9%
H
0.8
1.0
|
L
 -28.8%
H
0.8
1.4
|
L
 -19.7%
H
0.8
4.4
|
L
 -95.4%
H
0.8
22
|
L
 -99.6%
H
0.8
276.8
|
L
 -99.9%
H
0.8
2812.5
|
L
 -100.0%
H
0.8
379518072.3
|
| GRI Bio Inc |
|
2.6
|
1.5
|
L
 -2.0%
H
1.5
1.6
|
L
 -8.6%
H
1.4
1.6
|
L
 -20.9%
H
1.4
2.0
|
L
 -43.3%
H
1.4
2.6
|
L
 -97.4%
H
1.4
80.4
|
L
 -100.0%
H
1.4
166550.0
|
L
 -100.0%
H
1.4
13462627.3
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
311.0
|
5.3
|
L
 3.5%
H
5.1
5.4
|
L
 7.0%
H
4.7
5.4
|
L
 -8.3%
H
4.7
6.2
|
L
 -46.6%
H
4.7
10.6
|
L
 -83.8%
H
4.7
50.4
|
L
 -95.9%
H
4.7
413
|
L
 -99.6%
H
4.7
1301.2
|
L
H
4.7
1666
|
| Galapagos NV (ADR) |
|
1,896.5
|
28.8
|
L
 -1.5%
H
28.8
29.3
|
L
 -2.4%
H
28.8
30.2
|
L
 -0.6%
H
28.7
30.9
|
L
 -1.2%
H
26.4
30.9
|
L
 -12.2%
H
26.4
37.8
|
L
 -33.0%
H
22.4
44.3
|
L
 -52.1%
H
22.4
72.1
|
L
 -45.6%
H
22.4
274.0
|
| Genmab (ADR) |
|
17,712.1
|
28.9
|
L
 1.7%
H
28.8
29.3
|
L
 -0.8%
H
27.9
29.3
|
L
 12.7%
H
25.3
29.8
|
L
 4.2%
H
23.6
29.8
|
L
 32.3%
H
21
35.4
|
L
 -30.6%
H
17.2
42.7
|
L
 -35.0%
H
17.2
49.1
|
L
 70.2%
H
12.1
49.1
|
| Halozyme Therapeutics Inc |
|
9,230.5
|
77.8
|
L
 -1.0%
H
77.4
79.3
|
L
 2.6%
H
75.5
79.6
|
L
 12.8%
H
68.9
82.3
|
L
 13.8%
H
62.4
82.3
|
L
 35.3%
H
57.3
82.3
|
L
 81.4%
H
32.8
82.3
|
L
 83.2%
H
29.9
82.3
|
L
 742.2%
H
8.2
82.3
|
| HCW Biologics Inc |
|
5.3
|
3.3
|
L
 -1.2%
H
3.1
3.6
|
L
 -22.3%
H
3.1
4.5
|
L
 -52.0%
H
3.1
7.1
|
L
 39.8%
H
1.8
23.9
|
L
 -87.1%
H
1.5
44.1
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
24.5
|
2.1
|
L
 -3.2%
H
2.1
2.2
|
L
 -12.6%
H
2
2.4
|
L
 -34.9%
H
2
3.3
|
L
 -41.1%
H
2
3.9
|
L
 29.0%
H
1.1
9.1
|
L
 -78.3%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
89.0
|
0.5
|
L
 -2.1%
H
0.5
0.5
|
L
 6.8%
H
0.4
0.5
|
L
 9.3%
H
0.4
0.5
|
L
 -53.9%
H
0.4
1.3
|
L
 -75.3%
H
0.4
2.0
|
L
 -65.9%
H
0.4
3.9
|
L
 -96.4%
H
0.4
13.1
|
L
 -97.2%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
18.2
|
2.9
|
L
 -5.6%
H
2.8
3.0
|
L
 -16.2%
H
2.8
3.5
|
L
 -22.1%
H
2.8
4.4
|
L
 -14.9%
H
2.8
10.8
|
L
 -87.0%
H
2.1
31.9
|
L
 -96.2%
H
2.1
109.2
|
L
 -97.3%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
172.6
|
0.6
|
L
 -4.5%
H
0.6
0.7
|
L
 -5.9%
H
0.6
0.7
|
L
 -23.8%
H
0.6
0.9
|
L
 -8.6%
H
0.6
1.5
|
L
 -72.2%
H
0.6
2.8
|
L
 -78.6%
H
0.6
10.0
|
L
 -93.6%
H
0.6
17.5
|
L
H
0.6
17.5
|
| Immucell Corp |
|
100.7
|
11.1
|
L
 -0.6%
H
11.0
11.7
|
L
 3.7%
H
10.7
11.7
|
L
 14.3%
H
9.5
12.1
|
L
 42.3%
H
7.7
12.1
|
L
 63.0%
H
4.5
12.1
|
L
 106.9%
H
3.3
12.1
|
L
 14.3%
H
3.3
12.1
|
L
 63.7%
H
3.3
13.2
|
| InflaRx N.V. |
|
265.1
|
1.8
|
L
 -0.6%
H
1.8
1.9
|
L
 -10.9%
H
1.8
2.1
|
L
 -5.3%
H
1.8
2.6
|
L
 12.5%
H
1.5
3.0
|
L
 114.3%
H
0.7
3.0
|
L
 -57.3%
H
0.7
4.3
|
L
 -32.1%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
67.3
|
6.0
|
L
 -0.5%
H
5.7
6.0
|
L
 -0.7%
H
5.3
6.0
|
L
 -0.3%
H
5.3
6.3
|
L
 -0.7%
H
5.1
6.3
|
L
 -59.9%
H
3.9
18
|
L
 -92.1%
H
3.9
77.2
|
L
 -95.7%
H
3.9
210
|
L
H
3.9
451.3
|
| Immunome Inc |
|
2,591.2
|
22.9
|
L
 0.4%
H
22.5
23.1
|
L
 -0.2%
H
21.6
23.4
|
L
 19.3%
H
19
25
|
L
 -3.8%
H
17.8
25
|
L
 106.7%
H
8.7
27.7
|
L
 221.3%
H
5.2
31.0
|
L
 42.5%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
6.7
|
1.6
|
L
 -4.8%
H
1.5
1.7
|
L
 -17.6%
H
1.5
2.0
|
L
 -11.7%
H
1.5
2.2
|
L
 -47%
H
1.5
3
|
L
 -83.0%
H
1.5
9.4
|
L
 -91.4%
H
1.5
54.8
|
L
 -99.4%
H
1.5
281.3
|
L
 -100.0%
H
1.5
4410
|
| Immunovant Inc |
|
8,017.3
|
39.1
|
L
 -1.2%
H
38.8
39.4
|
L
 -2.1%
H
38.0
41.2
|
L
 2.5%
H
37.4
41.2
|
L
 32.4%
H
25.8
41.2
|
L
 117.7%
H
14.3
41.2
|
L
 75.3%
H
12.7
45.6
|
L
 284.7%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
11.8
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -14.6%
H
1.2
1.5
|
L
 -15.8%
H
1.2
1.5
|
L
 -18%
H
1.2
1.9
|
L
 -48.1%
H
1.2
2.7
|
L
 -26.8%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,070.7
|
85.9
|
L
 -1.9%
H
85.3
87.5
|
L
 -5.8%
H
83.2
91.5
|
L
 -7.9%
H
83.2
106.4
|
L
 -25.4%
H
83.2
151.0
|
L
 275.9%
H
20.6
155.3
|
L
 241.4%
H
10.8
155.3
|
L
 198.6%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
51.0
|
10.2
|
L
 -7.5%
H
10.2
11.2
|
L
 -7.7%
H
10.2
11.3
|
L
 -16.4%
H
10.2
12.6
|
L
 -9.7%
H
9.5
13.4
|
L
 -51.4%
H
8.5
21.5
|
L
 -44.0%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
48.9
|
1.8
|
L
 -6.6%
H
1.8
2.0
|
L
 -11.1%
H
1.8
2.1
|
L
 28.7%
H
1.3
2.2
|
L
 28.7%
H
1.2
2.2
|
L
 -23.3%
H
1.1
3.2
|
L
 -79.4%
H
1.1
14.7
|
L
 -91.7%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
2,308.4
|
5.2
|
L
 -5.7%
H
5.1
5.6
|
L
 9.1%
H
4.4
5.6
|
L
 27.3%
H
3.8
5.6
|
L
 46.5%
H
3.3
5.6
|
L
 65.2%
H
1.8
5.6
|
L
 -32.6%
H
1.6
18.3
|
L
 -77.8%
H
1.6
28.0
|
L
 -36.3%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
67.3
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -3.4%
H
1.4
1.5
|
L
 -4%
H
1.4
1.7
|
L
 10.8%
H
1.2
2.0
|
L
 -15.3%
H
1.0
3.3
|
L
 -46.9%
H
0.3
3.3
|
L
 -89.1%
H
0.3
10.7
|
L
 7100%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
387.8
|
2.2
|
L
 -4.0%
H
2.1
2.3
|
L
 -0.9%
H
2.1
2.4
|
L
 -6.5%
H
2.1
2.6
|
L
 -11.9%
H
2.0
2.6
|
L
 270.7%
H
0.4
3.0
|
L
 -31.1%
H
0.3
5.5
|
L
 -92.5%
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,839.0
|
74.3
|
L
 -1.7%
H
72.9
75.3
|
L
 -2.2%
H
72.2
77.5
|
L
 5.0%
H
69.4
82.5
|
L
 6.6%
H
63.8
82.5
|
L
 22.4%
H
40
99.5
|
L
 62.2%
H
25.6
99.5
|
L
 46.9%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
182.7
|
0.6
|
L
 -8.8%
H
0.6
0.7
|
L
 -24.4%
H
0.6
0.8
|
L
 -31.9%
H
0.6
1
|
L
 -61.3%
H
0.6
1.6
|
L
 -18.4%
H
0.5
3.1
|
L
 -57.5%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,807.8
|
35.5
|
L
 3.1%
H
34.1
36.3
|
L
 2.5%
H
33.3
36.3
|
L
 21.1%
H
29.1
36.3
|
L
 18.6%
H
27.6
36.3
|
L
 -4.3%
H
27.6
40.7
|
L
 -45.2%
H
23.2
77.0
|
L
 2.4%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
57.5
|
0.4
|
L
 -2.5%
H
0.4
0.4
|
L
 -11.4%
H
0.4
0.5
|
L
 2.6%
H
0.4
0.5
|
L
 -33.9%
H
0.4
0.6
|
L
 -77.1%
H
0.3
3.5
|
L
 -83.1%
H
0.3
3.5
|
L
 -89.1%
H
0.3
5
|
L
 -87.3%
H
0.3
8.0
|
| Inventiva (ADR) |
|
1,072.5
|
4.5
|
L
 1.3%
H
4.3
4.6
|
L
 1.6%
H
4.3
4.7
|
L
 29.3%
H
3.4
4.7
|
L
 -13.5%
H
3.4
6.1
|
L
 37.6%
H
2.9
8.0
|
L
 13.5%
H
1.5
8.0
|
L
 -68.7%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
952.6
|
15.6
|
L
 -3.9%
H
15.5
16.4
|
L
 -2.6%
H
15.5
16.5
|
L
 8.9%
H
14.3
16.9
|
L
 1.5%
H
13.0
16.9
|
L
 -40.8%
H
12.1
35.3
|
L
 22.1%
H
5.7
71.7
|
L
 -48.6%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
24.6
|
0.7
|
L
 -3.9%
H
0.7
0.8
|
L
 7.3%
H
0.6
1.0
|
L
 48%
H
0.3
1.0
|
L
 -24.5%
H
0.3
1.0
|
L
 -76.5%
H
0.3
3.3
|
L
 -50%
H
0.3
31.0
|
L
H
0.3
31.0
|
L
H
0.3
31.0
|
| Kamada Ltd |
|
404.4
|
7.0
|
L
 -3.7%
H
7
7.2
|
L
 -2.0%
H
6.9
7.3
|
L
 -2.5%
H
6.9
7.7
|
L
 -16.2%
H
6.9
8.7
|
L
 -8.3%
H
6.5
9.4
|
L
 37.5%
H
4.1
9.4
|
L
 26.5%
H
3.7
9.4
|
L
 82.1%
H
3.7
13.3
|
| Kodiak Sciences Inc |
|
2,623.3
|
41.9
|
L
 -1.2%
H
41.1
42.9
|
L
 -1.2%
H
39.4
44.9
|
L
 14.4%
H
33.5
44.9
|
L
 -7.2%
H
29.2
47
|
L
 651.3%
H
5.6
47.8
|
L
 475.0%
H
1.4
47.8
|
L
 -50.5%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
9,928.8
|
336.8
|
L
 -0.7%
H
332.0
341.7
|
L
 -3.8%
H
325
361.0
|
L
 -1.9%
H
325
382.5
|
L
 22.1%
H
252.0
382.5
|
L
 121.7%
H
130.5
382.5
|
L
 179.9%
H
94.0
382.5
|
L
 440.9%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
142.6
|
2.2
|
L
 1.4%
H
2.2
2.3
|
L
 -1.8%
H
2.2
2.3
|
L
 -17.3%
H
2.1
2.8
|
L
 -16.4%
H
1.9
2.8
|
L
 -18.3%
H
0.4
3.9
|
L
 -98.6%
H
0.2
175
|
L
 -99.9%
H
0.2
2940
|
L
 -100.0%
H
0.2
142625
|
| Kura Oncology Inc |
|
935.7
|
10.5
|
L
 -3.2%
H
10.5
10.9
|
L
 -7.0%
H
10.5
11.2
|
L
 1.7%
H
10.2
12.2
|
L
 10.6%
H
8.4
12.2
|
L
 58.0%
H
5.5
12.5
|
L
 -4.3%
H
5.4
24.2
|
L
 -43.2%
H
5.4
24.2
|
L
 144.0%
H
3.8
43
|
| Kymera Therapeutics Inc |
|
9,076.3
|
110.3
|
L
 -2.7%
H
110.2
113.6
|
L
 -3.3%
H
110.2
119.8
|
L
 11.0%
H
94.6
130.1
|
L
 24.3%
H
69.5
130.1
|
L
 141.1%
H
36.7
130.1
|
L
 409.9%
H
9.6
130.1
|
L
 92.3%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
166.8
|
14.6
|
L
 3.2%
H
13.7
14.6
|
L
 8.6%
H
12.8
14.6
|
L
 4.3%
H
11.9
15.3
|
L
 26.6%
H
10.6
15.3
|
L
 48.1%
H
4.9
17.4
|
L
 -66.0%
H
2.9
79
|
L
 -96.9%
H
2.9
614
|
L
 -96.0%
H
2.9
792.5
|
| Longeveron Inc (Class A) |
|
19.9
|
0.6
|
L
 3.3%
H
0.6
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 -21.3%
H
0.6
0.9
|
L
 -38.8%
H
0.6
1.0
|
L
 -62.3%
H
0.5
1.8
|
L
 -98.1%
H
0.5
43.0
|
L
 -99.0%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
91.2
|
5.0
|
L
 -7.8%
H
4.9
5.4
|
L
 -15.1%
H
4.9
6.0
|
L
 -33.3%
H
4.9
8.4
|
L
 30.3%
H
3.3
8.4
|
L
 17.4%
H
2.4
8.4
|
L
 18.8%
H
0.6
8.4
|
L
 -82.4%
H
0.6
49.5
|
L
 -58.4%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
71.3
|
0.7
|
L
 -9.5%
H
0.7
0.7
|
L
 -10.7%
H
0.7
0.8
|
L
 -9.5%
H
0.6
0.8
|
L
 -22.1%
H
0.5
1.4
|
L
 91.4%
H
0.2
3.7
|
L
 -78.2%
H
0.2
5
|
L
 -95.1%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
417.6
|
4.0
|
L
 2.3%
H
3.9
4.2
|
L
 5.5%
H
3.5
4.2
|
L
 9.8%
H
2.9
4.3
|
L
 -11.8%
H
2.9
4.7
|
L
 18.9%
H
2.7
6.4
|
L
 24.5%
H
1.6
13.7
|
L
 -59.7%
H
1.5
15.3
|
L
 -88.6%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
314.6
|
12.8
|
L
 -2.1%
H
12.7
14.1
|
L
 -10.0%
H
12.7
14.4
|
L
 7.3%
H
11.5
16.8
|
L
 -48.2%
H
11.5
25.0
|
L
 24.9%
H
9.3
45
|
L
 -80.1%
H
7.7
65.1
|
L
 -95.9%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
118.9
|
1.8
|
L
 -1.7%
H
1.8
1.8
|
L
 -4.8%
H
1.7
1.9
|
L
 -4.3%
H
1.7
2.0
|
L
 -20.3%
H
1.7
2.3
|
L
 -30.0%
H
1.6
4.7
|
L
 -30.0%
H
0.8
4.7
|
L
 -75.7%
H
0.8
9.6
|
L
 -96.4%
H
0.8
403.7
|
| Seres Therapeutics Inc |
|
51.1
|
5.3
|
L
 0.6%
H
5.2
5.3
|
L
 -3.1%
H
5
5.7
|
L
 -20%
H
5
8.3
|
L
 -37.4%
H
5
8.7
|
L
 -57.4%
H
5
30.0
|
L
 14.5%
H
0.4
30.0
|
L
 -33.6%
H
0.4
30.0
|
L
 -84.7%
H
0.4
38.5
|
| Magenta Therapeutics Inc |
|
-
|
102.8
|
L
 -2.8%
H
102.4
106.6
|
L
 2.9%
H
91.0
108.0
|
L
 17.6%
H
84.6
108.0
|
L
 12.6%
H
68.9
108.0
|
L
 395.5%
H
18.1
108.0
|
L
 702.8%
H
10.9
108.0
|
L
 -14.5%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,126.1
|
12.2
|
L
 -2.9%
H
12.1
12.5
|
L
 -3.2%
H
11.9
12.9
|
L
 5.9%
H
11.3
15.4
|
L
 21.2%
H
8.8
15.4
|
L
 41.6%
H
6.6
15.4
|
L
 69.1%
H
3.5
15.4
|
L
 -16.7%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,381.2
|
27.0
|
L
 -1.9%
H
26.9
27.5
|
L
 -1.1%
H
26.4
27.8
|
L
 6.5%
H
24.6
31.1
|
L
 -6.6%
H
22.3
32.1
|
L
 102.5%
H
12.6
47.7
|
L
 78.8%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
753.5
|
112.5
|
L
 -1.0%
H
110.3
116.6
|
L
 3.5%
H
104
116.6
|
L
 63.8%
H
68.2
116.6
|
L
 111.0%
H
50.1
116.6
|
L
 148.7%
H
29.2
116.6
|
L
 2791.5%
H
1.4
116.6
|
L
 307.5%
H
1.4
116.6
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
20.7
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -12.1%
H
1.2
1.4
|
L
 -9.5%
H
1.2
1.7
|
L
 -19.5%
H
1.2
1.7
|
L
 -21.5%
H
0.8
2.5
|
L
 -81.2%
H
0.8
9.7
|
L
 -94.5%
H
0.7
23.0
|
L
 -97.6%
H
0.7
135.5
|
| Moderna |
|
23,041.4
|
58.1
|
L
 -2.7%
H
57.7
59.9
|
L
 -15.0%
H
57.7
67.4
|
L
 -2.1%
H
57.7
85.6
|
L
 4.4%
H
43.7
85.6
|
L
 77.4%
H
22.3
85.6
|
L
 -54.1%
H
22.3
170.5
|
L
 -82.0%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
1,047.3
|
7.1
|
L
H
7.0
7.2
|
L
 0.9%
H
6.7
7.3
|
L
 35.2%
H
5.2
7.3
|
L
 92.4%
H
3.3
7.3
|
L
 180.6%
H
2.0
7.3
|
L
 -43.2%
H
1.7
12.6
|
L
 -83.0%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
122.1
|
1.1
|
L
 -7.3%
H
1.1
1.2
|
L
 -19.7%
H
1.1
1.5
|
L
 -3.4%
H
1.1
1.5
|
L
 28.1%
H
0.8
1.5
|
L
 -49.1%
H
0.6
2.4
|
L
 -76.9%
H
0.6
5.5
|
L
 -80.5%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
26.0
|
1.1
|
L
 -1.7%
H
1.1
1.2
|
L
 -7.3%
H
1.1
1.3
|
L
 -26.0%
H
1.1
1.9
|
L
 119.2%
H
0.3
4.9
|
L
 -42.7%
H
0.3
4.9
|
L
 -99.4%
H
0.3
188.4
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,114.0
|
16.3
|
L
 -0.7%
H
16.2
16.6
|
L
 -10.6%
H
16.1
19.4
|
L
 5.2%
H
13.1
19.4
|
L
 3.6%
H
13.1
19.4
|
L
 8.1%
H
12.7
21.5
|
L
 237.5%
H
1.0
22
|
L
 127.3%
H
1.0
22
|
L
 289.0%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
148.9
|
4.0
|
L
 -3.4%
H
4.0
4.0
|
L
 1.5%
H
3.9
4.1
|
L
 0.5%
H
3.7
4.2
|
L
 -8.5%
H
3.7
4.5
|
L
 6.4%
H
3.4
5.4
|
L
 -40.6%
H
3.3
12.7
|
L
 -79.5%
H
3.3
32.0
|
L
 -84.7%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
47.9
|
0.3
|
L
 -3.2%
H
0.3
0.3
|
L
 -9.1%
H
0.3
0.3
|
L
 -6.3%
H
0.3
0.4
|
L
 -6.3%
H
0.2
0.4
|
L
 -83.0%
H
0.2
2.4
|
L
 -76.7%
H
0.2
5.0
|
L
 -89.2%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
216.0
|
1.7
|
L
H
1.7
1.7
|
L
 -2.3%
H
1.6
1.8
|
L
 -26.4%
H
1.6
2.4
|
L
 -40.8%
H
1.6
3.2
|
L
 129.7%
H
0.6
4.3
|
L
 -47.7%
H
0.6
4.3
|
L
 -81.6%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
17,364.0
|
172.7
|
L
 -3.6%
H
171.8
181
|
L
 0.4%
H
169.0
181
|
L
 6.9%
H
160.4
181.2
|
L
 31.6%
H
126.5
181.2
|
L
 30.1%
H
122.1
181.2
|
L
 74.8%
H
84.2
181.2
|
L
 76.0%
H
71.9
181.2
|
L
 248.8%
H
37.3
181.2
|
| Nkarta Inc |
|
172.4
|
2.4
|
L
 -6.6%
H
2.4
2.6
|
L
 -9.4%
H
2.4
2.7
|
L
 -13.6%
H
2.4
3.7
|
L
 -22.0%
H
2.3
3.7
|
L
 15.9%
H
1.7
3.7
|
L
 11.6%
H
1.3
16.2
|
L
 -92.2%
H
1.3
40.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
36.1
|
L
 -1.6%
H
34.7
36.7
|
L
 -8.5%
H
34.7
39.6
|
L
 12.0%
H
29.7
43.7
|
L
 32.4%
H
24.9
43.7
|
L
 64.6%
H
15.9
43.7
|
L
 159.8%
H
12.2
43.7
|
L
 -77.9%
H
7.5
169.6
|
L
 -76.8%
H
7.5
399.4
|
| MetaVia Inc |
|
8.2
|
1.6
|
L
H
1.5
1.6
|
L
 -14.6%
H
1.5
1.9
|
L
 0.6%
H
1.4
2.6
|
L
 -1.9%
H
1.0
4.3
|
L
 -79.5%
H
1.0
19.0
|
L
 -96.5%
H
1.0
74.3
|
L
 -100.0%
H
1.0
13068
|
L
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,449.2
|
23.6
|
L
 0.5%
H
23.2
24.0
|
L
 -1.1%
H
22.5
24.0
|
L
 26.5%
H
18.4
25.1
|
L
 41.9%
H
14.2
25.1
|
L
 109.8%
H
8.2
25.1
|
L
 134.4%
H
4.2
29.6
|
L
 -23.1%
H
4.2
37.4
|
L
H
4.2
52.4
|
| Intellia Therapeutics Inc |
|
1,555.1
|
11.1
|
L
 -3.0%
H
11.1
11.5
|
L
 -14.7%
H
10.9
12.6
|
L
 -29.3%
H
10.9
18.5
|
L
 -32.8%
H
10.9
18.5
|
L
 -17.5%
H
8.0
28.3
|
L
 -74.3%
H
5.9
43.6
|
L
 -92.5%
H
5.9
180.6
|
L
 -39.8%
H
5.9
202.7
|
| Natera Inc |
|
37,840.4
|
264.2
|
L
 -1.1%
H
257.8
266
|
L
 -4.7%
H
255.7
282
|
L
 15.5%
H
224.4
288.0
|
L
 27.2%
H
184.8
288.0
|
L
 88.8%
H
131.8
288.0
|
L
 435.8%
H
36.9
288.0
|
L
 126.2%
H
26.1
288.0
|
L
 1961.0%
H
7.4
288.0
|
| Novavax Inc |
|
1,300.7
|
7.9
|
L
 -2.1%
H
7.9
8.2
|
L
 -6.2%
H
7.8
8.4
|
L
 -12.1%
H
7.8
10.1
|
L
 -6.4%
H
7.7
11.6
|
L
 9.6%
H
6.2
12.0
|
L
 -2.9%
H
3.5
23.9
|
L
 -96.2%
H
3.5
277.8
|
L
 -94.6%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
5.7
|
1.4
|
L
 5.4%
H
1.3
1.4
|
L
 0.7%
H
1.2
1.4
|
L
 -25.7%
H
1.2
2.0
|
L
 -36.2%
H
1.2
2.4
|
L
 -99.9%
H
1.2
2600
|
L
 -100.0%
H
1.2
824000
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Insight Molecular Diagnostics Inc |
|
161.1
|
5.0
|
L
 -0.2%
H
4.9
5.2
|
L
 3.5%
H
4.6
5.2
|
L
 -7.6%
H
4.3
6.1
|
L
 33.1%
H
3.3
6.9
|
L
 75.7%
H
2.3
8.5
|
L
 14.2%
H
1.9
8.5
|
L
 -95.4%
H
1.9
110
|
L
 -93.4%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
79.8
|
1.5
|
L
 5.6%
H
1.4
1.6
|
L
 2.0%
H
1.3
1.6
|
L
 -3.2%
H
1.3
1.9
|
L
 -6.2%
H
1.3
1.9
|
L
 -44.7%
H
1.3
3.4
|
L
 23.6%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
99.1
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -7.8%
H
0.8
0.9
|
L
 -9.8%
H
0.8
1.1
|
L
 -27.8%
H
0.8
1.2
|
L
 -33.1%
H
0.8
1.5
|
L
 -70.8%
H
0.3
3.1
|
L
 -67.3%
H
0.3
3.4
|
L
 -71.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
8.2
|
0.5
|
L
 -11.5%
H
0.5
0.6
|
L
 -16.9%
H
0.5
0.7
|
L
 -39.3%
H
0.5
0.9
|
L
 -58.1%
H
0.5
3.2
|
L
 -66.7%
H
0.5
3.3
|
L
 -97.9%
H
0.5
27.5
|
L
 -99.6%
H
0.5
169.3
|
L
 -100.0%
H
0.5
25368.8
|
| VivoSim Labs Inc |
|
1.6
|
0.5
|
L
 2.2%
H
0.4
0.5
|
L
 -45.9%
H
0.4
0.7
|
L
 -59.3%
H
0.4
1.6
|
L
 -68.9%
H
0.4
1.7
|
L
 -76.9%
H
0.4
5.3
|
L
 -98.0%
H
0.3
24.6
|
L
 -99.5%
H
0.3
99.6
|
L
 -100.0%
H
0.3
1197.6
|
| Passage Bio Inc |
|
15.8
|
4.9
|
L
 0.2%
H
4.7
5
|
L
 0.2%
H
4.7
5.0
|
L
 -14.0%
H
3.3
6.3
|
L
 -19.7%
H
3.3
6.3
|
L
 -13.2%
H
3.3
20
|
L
 -75.2%
H
3.3
35.8
|
L
 -98.1%
H
3.3
268.6
|
L
H
3.3
764.6
|
| Vaxcyte Inc |
|
8,086.3
|
56
|
L
 -3.5%
H
56.0
58.6
|
L
 -1.3%
H
54.6
58.6
|
L
 7.5%
H
51.5
61.8
|
L
 -7.9%
H
45.3
61.8
|
L
 56.8%
H
29.1
65
|
L
 15.4%
H
27.7
121.1
|
L
 148.7%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
132.8
|
1.9
|
L
 -9.4%
H
1.9
2.1
|
L
 -20%
H
1.9
2.4
|
L
 4.9%
H
1.6
2.6
|
L
 15.7%
H
1.3
2.6
|
L
 37.1%
H
1.0
7.8
|
L
 -75.4%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,896.6
|
5.3
|
L
 -3.1%
H
5.2
5.5
|
L
 3.9%
H
4.8
5.6
|
L
 -1.1%
H
4.8
6.0
|
L
 34.3%
H
3.5
6.0
|
L
 250%
H
1.5
6.0
|
L
 297.0%
H
0.7
6.0
|
L
 -4.3%
H
0.7
6.5
|
L
 -77.8%
H
0.7
32.9
|
| Phio Pharma Corp |
|
12.3
|
1.1
|
L
 -6.2%
H
1.1
1.1
|
L
 19.1%
H
0.9
1.1
|
L
 1.0%
H
0.8
1.1
|
L
 -15.2%
H
0.8
1.3
|
L
 -57.9%
H
0.8
4.2
|
L
 -95.6%
H
0.6
29.1
|
L
 -99.5%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,401.1
|
34.4
|
L
 -0.3%
H
34.0
34.9
|
L
 -2.3%
H
33.0
35.5
|
L
 4.1%
H
32.1
36.6
|
L
 14.4%
H
26.7
36.6
|
L
 48.6%
H
19.1
36.6
|
L
 107.9%
H
11.5
36.6
|
L
 138.0%
H
1.8
36.6
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
68.1
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 -5.2%
H
1.1
1.2
|
L
 -14.7%
H
1.1
1.3
|
L
 -29.9%
H
1.1
2.0
|
L
 -93.7%
H
1.1
20.2
|
L
 -95.7%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
20.0
|
1.9
|
L
 -5.1%
H
1.8
2.0
|
L
 5.7%
H
1.7
2.0
|
L
 -8.4%
H
1.6
2.4
|
L
 -44.8%
H
1.6
3.9
|
L
 -63.2%
H
1.6
5.7
|
L
 -71.1%
H
0.7
8.5
|
L
 -93.4%
H
0.7
29.4
|
L
 -98.5%
H
0.7
169.6
|
| ProMIS Neurosciences Inc |
|
125.5
|
14.0
|
L
 -3.5%
H
13.7
14.4
|
L
 -0.1%
H
12.9
16.7
|
L
 31.0%
H
10.2
16.7
|
L
 25.9%
H
9.1
16.7
|
L
 -31.8%
H
6.3
27.4
|
L
 -87.7%
H
6.3
120.3
|
L
 -94.1%
H
6.3
322.8
|
L
 -93.4%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
70.9
|
1.3
|
L
 1.5%
H
1.3
1.4
|
L
 -5%
H
1.3
1.4
|
L
 16.7%
H
1.1
1.5
|
L
 -10.1%
H
1.0
1.5
|
L
 4.7%
H
1.0
1.9
|
L
 -79.8%
H
0.8
9.7
|
L
 -96.1%
H
0.8
37.3
|
L
H
0.8
63.2
|
| Prelude Therapeutics Inc |
|
312.2
|
3.9
|
L
 -3.0%
H
3.9
4.1
|
L
 -12.1%
H
3.9
4.4
|
L
 -9.3%
H
3.9
5.7
|
L
 -9.1%
H
3.4
5.7
|
L
 355.8%
H
0.8
5.7
|
L
 -14.2%
H
0.6
6.8
|
L
 -86.6%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
558.1
|
3.1
|
L
 -1.0%
H
3.0
3.2
|
L
 -11.5%
H
2.9
3.5
|
L
 -8.3%
H
2.9
4.8
|
L
 -22.0%
H
2.7
4.8
|
L
 -31.8%
H
2.7
6.9
|
L
 -79.4%
H
1.1
15.8
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
314.0
|
1.5
|
L
 -4.4%
H
1.5
1.6
|
L
 -4.4%
H
1.5
1.7
|
L
 -15.9%
H
1.5
2.2
|
L
 -26.8%
H
1.5
2.2
|
L
 -49.8%
H
1.5
3.6
|
L
 -86.8%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
441.9
|
8.4
|
L
 -3.5%
H
8.4
8.8
|
L
 0.1%
H
8.1
8.9
|
L
 -7.8%
H
8.1
10.2
|
L
 -21.3%
H
7.7
11.8
|
L
 29.3%
H
6.5
11.8
|
L
 -87.0%
H
4.3
70.1
|
L
 -83.6%
H
4.3
79.8
|
L
 -84.1%
H
4.3
79.8
|
| Quince Therapeutics Inc |
|
18.1
|
18.5
|
L
 -1.3%
H
17.5
18.9
|
L
 -0.2%
H
17.5
20.7
|
L
 1893.6%
H
0.9
20.7
|
L
 1253.3%
H
0.8
20.7
|
L
 4.8%
H
0.8
45.5
|
L
 17.3%
H
0.8
45.5
|
L
 -97.1%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
2,776.3
|
40.4
|
L
 0.7%
H
39.4
40.9
|
L
 -1.5%
H
38.2
41.9
|
L
 -9.0%
H
38.2
50.5
|
L
 127.1%
H
16.6
50.5
|
L
 183.4%
H
8.7
71.5
|
L
 303.0%
H
3.7
71.5
|
L
 52.4%
H
3.7
71.5
|
L
 463.2%
H
3.7
82.5
|
| Rani Therapeutics Holdings Inc |
|
101.2
|
0.9
|
L
 30.4%
H
0.7
0.9
|
L
 32.4%
H
0.6
0.9
|
L
 16.9%
H
0.6
0.9
|
L
 -5.3%
H
0.6
1.1
|
L
 104.6%
H
0.4
3.9
|
L
 -79.1%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
360.3
|
3.3
|
L
 -2.9%
H
3.3
3.5
|
L
 -9.6%
H
3.3
3.6
|
L
 -4.6%
H
3.1
4.3
|
L
 -13.2%
H
2.5
4.3
|
L
 -2.1%
H
2.5
5.5
|
L
 -82.1%
H
2.2
32.5
|
L
 -93.3%
H
2.2
49.7
|
L
 -90.8%
H
2.2
67.5
|
| Replimune Grp Inc |
|
902.4
|
10.8
|
L
 -2.3%
H
10.7
11.2
|
L
 11.1%
H
8.9
11.2
|
L
 -3.9%
H
8.9
12.5
|
L
 373.6%
H
2.3
12.5
|
L
 283.9%
H
1.5
12.5
|
L
 -48.2%
H
1.5
21.6
|
L
 -67.4%
H
1.5
37.0
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.5
|
1.2
|
L
H
1.1
1.2
|
L
 5.5%
H
1.1
1.2
|
L
 9.5%
H
1.0
1.2
|
L
 -0.9%
H
0.9
1.2
|
L
 -90.6%
H
0.9
12.7
|
L
 -100.0%
H
0.9
5417.6
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
4,199.7
|
19.3
|
L
 -0.2%
H
18.9
19.5
|
L
 -1.2%
H
18.9
20.4
|
L
 11.5%
H
16.6
20.8
|
L
 16.7%
H
11.6
20.8
|
L
 419.4%
H
3.0
20.8
|
L
 55.5%
H
1.8
20.8
|
L
 -43.7%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Rallybio Corp |
|
88.2
|
16.6
|
L
 -1.7%
H
16.5
16.9
|
L
 3.0%
H
15.7
17.1
|
L
 4.3%
H
15.6
17.1
|
L
 94.4%
H
8.4
17.6
|
L
 326.2%
H
3.2
17.6
|
L
 -66.3%
H
1.8
50.6
|
L
H
1.8
206.2
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
8.0
|
8.4
|
L
H
8.0
9.0
|
L
 -3.5%
H
8.0
9.0
|
L
 68%
H
4.1
10.7
|
L
 -2.3%
H
3.8
10.7
|
L
 -11.0%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
 -100.0%
H
3.8
3901941.1
|
L
H
3.8
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,581.7
|
3.0
|
L
 -3.3%
H
3.0
3.1
|
L
 -10.0%
H
2.8
3.3
|
L
 -6.3%
H
2.8
4.1
|
L
 -20.1%
H
2.8
4.1
|
L
 -54.4%
H
2.8
7.2
|
L
 -80.7%
H
2.8
15.9
|
L
 -91.7%
H
2.8
37.0
|
L
H
2.8
42.8
|
| SAB Biotherapeutics Inc |
|
273.7
|
3.6
|
L
 -1.7%
H
3.5
3.6
|
L
 -1.1%
H
3.5
3.8
|
L
 -8.9%
H
3.5
4.1
|
L
 -10.3%
H
3.3
4.6
|
L
 37.2%
H
1.9
5.2
|
L
 321.2%
H
0.4
6.6
|
L
 -64.0%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
868.3
|
3.1
|
L
 -1.3%
H
3.1
3.2
|
L
 -12.1%
H
3.1
3.5
|
L
 -7.1%
H
3.1
4.2
|
L
 -15.5%
H
2.6
4.2
|
L
 -35.9%
H
2.6
6.6
|
L
 -49.0%
H
1.3
12
|
L
 -83.0%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
46.4
|
1.0
|
L
 -5.0%
H
1.0
1.0
|
L
 -12.7%
H
1.0
1.1
|
L
 -22.6%
H
1.0
1.4
|
L
 -43.2%
H
1.0
1.7
|
L
 -62.8%
H
1.0
5.0
|
L
 -95.6%
H
1.0
42.2
|
L
 -99.2%
H
1.0
146.2
|
L
 -94.8%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
113.8
|
2.1
|
L
 -1.4%
H
2.0
2.1
|
L
 -4.2%
H
2.0
2.2
|
L
 17.6%
H
1.6
2.3
|
L
 4.6%
H
1.6
2.3
|
L
 -3.7%
H
1.6
2.4
|
L
 -59.4%
H
1.5
5.3
|
L
 -94.0%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,259.0
|
8.1
|
L
H
8.0
8.3
|
L
 -6.3%
H
7.9
8.7
|
L
 -18.3%
H
7.9
11
|
L
 18%
H
5.8
11
|
L
 -33.3%
H
5.6
14.6
|
L
 -20.8%
H
5.6
15.6
|
L
 -20.8%
H
5.6
15.6
|
L
 -20.8%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
797.4
|
8.1
|
L
 -4.3%
H
8.1
8.4
|
L
 -15.8%
H
8.1
9.4
|
L
 -2.4%
H
8.1
11.5
|
L
 -3.6%
H
6
11.5
|
L
 30.0%
H
3.8
11.5
|
L
 70.9%
H
1.8
15.1
|
L
 -81.5%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Decoy Therapeutics Inc |
|
2.6
|
5.0
|
L
 0.6%
H
4.9
5.4
|
L
 -19.9%
H
4.9
6.3
|
L
 -21.4%
H
4.9
13.5
|
L
 -8.5%
H
4.3
13.5
|
L
 -96.1%
H
4.3
415.8
|
L
 -99.7%
H
4.3
1526.4
|
L
 -100.0%
H
4.3
43200
|
L
 -100.0%
H
4.3
11412000
|
| Summit Therapeutics Inc |
|
11,440.6
|
14.7
|
L
 0.8%
H
14.7
15.7
|
L
 -2.2%
H
13.4
15.7
|
L
 3.2%
H
13.4
16.1
|
L
 -40.0%
H
12.6
24.7
|
L
 -44.5%
H
12.6
31.0
|
L
 637%
H
1.5
36.9
|
L
 85.9%
H
0.7
36.9
|
L
 106.2%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,953.9
|
22.1
|
L
 -2.6%
H
21.8
22.7
|
L
 -6.3%
H
21.8
24.4
|
L
 14.1%
H
19.2
25.2
|
L
 -0.1%
H
16.7
25.2
|
L
 113.9%
H
9.4
25.6
|
L
 3.7%
H
8.6
25.6
|
L
 50%
H
8.6
29.9
|
L
 77.1%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
738.8
|
28.7
|
L
 1.0%
H
26.6
28.7
|
L
 -8.9%
H
23.8
31.3
|
L
 23.6%
H
21.1
37.9
|
L
 -9.4%
H
10.8
37.9
|
L
 297.5%
H
6.3
37.9
|
L
 16.5%
H
5
38.8
|
L
 -80.1%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
13.7
|
0.4
|
L
 -4.4%
H
0.4
0.5
|
L
 -24.1%
H
0.4
0.6
|
L
 -55.1%
H
0.4
1.2
|
L
 -61.4%
H
0.4
1.2
|
L
 -77.9%
H
0.4
2.9
|
L
 -95.1%
H
0.4
16.9
|
L
 -55.6%
H
0.4
87.7
|
L
H
0.4
87.7
|
| Spruce Biosciences Inc |
|
122.8
|
44.6
|
L
 -2.4%
H
44.2
45.3
|
L
 -1.9%
H
42.7
46.3
|
L
 -18.5%
H
42.7
57
|
L
 -14.8%
H
42.7
60.3
|
L
 407.4%
H
7.3
240
|
L
 -73.2%
H
4.3
446.3
|
L
 -93.6%
H
4.3
754.5
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
73.5
|
1.3
|
L
 -8.0%
H
1.3
1.4
|
L
 -25.3%
H
1.3
1.7
|
L
 -42.5%
H
1.3
2.3
|
L
 -55.6%
H
1.3
3.1
|
L
 -47.3%
H
1.3
3.1
|
L
 -12.4%
H
0.5
3.2
|
L
 -91.2%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
5,787.7
|
48.3
|
L
 -5.1%
H
47.3
50.5
|
L
 -10.6%
H
47.3
53.9
|
L
 -1.8%
H
47.3
58.5
|
L
 2.1%
H
43.2
58.5
|
L
 20.8%
H
27.1
58.5
|
L
 586.1%
H
5.9
58.5
|
L
 46.1%
H
4.3
58.5
|
L
H
4.3
70
|
| Surrozen Inc |
|
252.2
|
21.7
|
L
 -5.5%
H
21.2
23.2
|
L
 -0.3%
H
20.0
23.4
|
L
 -8.2%
H
20.0
26.8
|
L
 -34.2%
H
20.0
35
|
L
 151.1%
H
8.2
35
|
L
 2425.6%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,803.7
|
29.0
|
L
 0.5%
H
28.0
29.2
|
L
 -3.2%
H
27.2
30.5
|
L
 -6.5%
H
27.2
33.7
|
L
 -19.3%
H
27.2
37
|
L
 113.4%
H
12.3
40.2
|
L
 141.5%
H
3.4
40.2
|
L
 -7.0%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
670.5
|
7.0
|
L
 -2.6%
H
6.7
7.2
|
L
 3.7%
H
6.4
7.8
|
L
 34.0%
H
5.1
7.8
|
L
 -9.4%
H
3.3
8.1
|
L
 777.5%
H
0.7
8.3
|
L
 162.9%
H
0.7
11.8
|
L
 -69.5%
H
0.7
23.4
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
4.1
|
1.6
|
L
 -1.3%
H
1.5
1.6
|
L
H
1.5
1.6
|
L
 -8.3%
H
1.4
1.9
|
L
 -13.9%
H
1.2
1.9
|
L
 -70.9%
H
1.2
8.6
|
L
 -99.8%
H
1.2
636
|
L
H
1.2
2076
|
L
H
1.2
2076
|
| Alaunos Therapeutics Inc |
|
4.8
|
2.0
|
L
 -6.7%
H
2.0
2.1
|
L
 -8.5%
H
2.0
2.2
|
L
 -9.7%
H
2.0
2.5
|
L
 -28.6%
H
1.9
3.1
|
L
 -34.8%
H
1.7
4.6
|
L
 306.3%
H
0.0
6.2
|
L
 -15.2%
H
0.0
6.2
|
L
 -56.6%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
58.8
|
0.9
|
L
 -4.3%
H
0.9
1.0
|
L
 -2.2%
H
0.9
1.0
|
L
 4.7%
H
0.8
1.3
|
L
 -28%
H
0.8
1.4
|
L
 -51.4%
H
0.8
2.6
|
L
 -59.6%
H
0.8
9.7
|
L
 -91.0%
H
0.8
14.7
|
L
H
0.8
14.7
|
| Bio-Techne |
|
11,184.1
|
71.8
|
L
 0.2%
H
71.5
71.8
|
L
 0.4%
H
71.5
72.1
|
L
 29.1%
H
55.8
72.1
|
L
 22.5%
H
43.2
72.1
|
L
 35.1%
H
43.2
72.2
|
L
 -19.7%
H
43.2
89.8
|
L
 -38.8%
H
43.2
136.0
|
L
 159.2%
H
23.9
136.0
|
| Instil Bio Inc |
|
49.2
|
7.3
|
L
H
7.2
7.4
|
L
 -4.9%
H
7.2
7.6
|
L
 -4.1%
H
7.2
8.1
|
L
 -13.8%
H
7.2
8.5
|
L
 -74.5%
H
5.7
33.8
|
L
 1150%
H
0.3
92
|
L
 -62.6%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
4,575.1
|
28.1
|
L
 -3.2%
H
27.9
28.7
|
L
 -7.1%
H
27.1
30.0
|
L
 -1.4%
H
27.1
33.5
|
L
 4.3%
H
19.3
34.4
|
L
 320.7%
H
5.8
34.4
|
L
 767.3%
H
1.0
34.4
|
L
H
1.0
34.4
|
L
H
1.0
34.4
|
| Entrada Therapeutics Inc |
|
238.7
|
6.2
|
L
 -4.8%
H
6.1
6.5
|
L
 -13.5%
H
6.1
7.1
|
L
 -13.0%
H
6.1
8.1
|
L
 -52.9%
H
5.6
16.5
|
L
 -3.6%
H
4.9
16.5
|
L
 -64.0%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,464.8
|
17.4
|
L
 -4.5%
H
17.2
18.1
|
L
 -4.3%
H
16.6
20.2
|
L
 -2.0%
H
16.2
20.2
|
L
 17.3%
H
13.1
20.2
|
L
 148%
H
6.6
20.2
|
L
 638.7%
H
1.0
20.2
|
L
 755.2%
H
0.5
20.2
|
L
H
0.5
20.2
|
| Taysha Gene Therapies Inc |
|
1,626.5
|
5.7
|
L
 -0.2%
H
5.6
5.7
|
L
 -8.6%
H
5.6
6.3
|
L
 -13.3%
H
5.3
7.1
|
L
 -15.8%
H
5.2
7.3
|
L
 115.2%
H
2.5
7.3
|
L
 720.3%
H
0.6
7.3
|
L
 -71.0%
H
0.5
21.9
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
5,866.6
|
94.2
|
L
 -1.7%
H
92.7
96.2
|
L
 1.7%
H
85.0
96.8
|
L
 10.6%
H
81.6
105.5
|
L
 49.1%
H
48
105.5
|
L
 162.9%
H
23.3
105.5
|
L
 275.2%
H
14.4
105.5
|
L
 -22.4%
H
11.5
140.0
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
5,973.3
|
47.1
|
L
 -0.3%
H
46.0
47.9
|
L
 2.8%
H
41.9
47.9
|
L
 42.8%
H
31.3
47.9
|
L
 106.1%
H
19.5
47.9
|
L
 262.2%
H
11.2
47.9
|
L
 -21.5%
H
6.8
63.6
|
L
 -74.7%
H
6.8
191.2
|
L
H
6.8
209.0
|
| Tyra Biosciences Inc |
|
1,819.2
|
30.6
|
L
 -4.0%
H
30.5
32.3
|
L
 -5.5%
H
30.1
33.7
|
L
 1.5%
H
28.9
33.7
|
L
 -18.1%
H
24.7
38.6
|
L
 197.3%
H
10.0
40.7
|
L
 90.2%
H
6.4
40.7
|
L
H
4.9
40.7
|
L
H
4.9
40.7
|
| Unicycive Therapeutics Inc |
|
152.6
|
5.6
|
L
 -2.1%
H
5.5
5.8
|
L
 11.0%
H
4.9
5.9
|
L
 -29.2%
H
3.9
8.6
|
L
 -27.8%
H
3.9
8.7
|
L
 24.6%
H
3.7
8.7
|
L
 -54.3%
H
2.0
18.2
|
L
 -79.6%
H
2.0
39.4
|
L
H
2.0
87.3
|
| TradeUP Acq Corp |
|
-
|
0.8
|
L
 -5%
H
0.8
0.8
|
L
 -1.3%
H
0.7
0.9
|
L
 -18.3%
H
0.7
1.1
|
L
 -57.8%
H
0.7
1.8
|
L
 -12.6%
H
0.7
3.2
|
L
 -93.0%
H
0.7
33
|
L
H
0.7
33
|
L
H
0.7
33
|
| UroGen Pharma Ltd |
|
2,049.2
|
42.1
|
L
 -3.9%
H
42.0
43.8
|
L
 5.7%
H
39.5
43.9
|
L
 20.2%
H
33.7
43.9
|
L
 61.4%
H
22.6
43.9
|
L
 148%
H
15.9
43.9
|
L
 352.7%
H
3.4
43.9
|
L
 162.9%
H
3.4
43.9
|
L
H
3.4
69.6
|
| United Therapeutics Corp |
|
26,249.2
|
527.1
|
L
 -1.6%
H
521.7
541.3
|
L
 -0.9%
H
521.7
543.6
|
L
 -2.1%
H
520.1
563.7
|
L
 -8.2%
H
520.1
609.4
|
L
 76.9%
H
272.1
609.4
|
L
 112.3%
H
208.6
609.4
|
L
 183.7%
H
158.4
609.4
|
L
 373.1%
H
74.3
609.4
|
| Vera Therapeutics Inc (Class A) |
|
2,588.5
|
36.1
|
L
 -3.0%
H
36.0
37.4
|
L
 -15.2%
H
36.0
42.6
|
L
 -6.2%
H
36.0
44.9
|
L
 -10.5%
H
30.6
44.9
|
L
 61.8%
H
19.1
56.1
|
L
 115.8%
H
9.2
56.1
|
L
 117.5%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,576.9
|
9.4
|
L
 -0.7%
H
9.3
9.6
|
L
 -2.7%
H
9.1
9.7
|
L
 -2.3%
H
9.1
10.6
|
L
 -12.4%
H
8.2
10.9
|
L
 63.2%
H
4.2
11.7
|
L
 -34.8%
H
4.2
14.5
|
L
 -75.0%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
1,057.2
|
19.5
|
L
 -2.7%
H
18.9
20.4
|
L
 7.9%
H
16.7
20.4
|
L
 30.6%
H
14.2
22.2
|
L
 27.4%
H
12.6
22.2
|
L
 851.7%
H
1.5
50.0
|
L
 482.4%
H
0.1
50.0
|
L
 38.5%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
517.6
|
5.9
|
L
 -1.8%
H
5.7
6.1
|
L
 2.8%
H
5.5
6.2
|
L
 38.6%
H
3.4
6.2
|
L
 -3.0%
H
3.4
6.3
|
L
 11.8%
H
3.4
11.2
|
L
 -40.5%
H
2.1
14.2
|
L
 -85.9%
H
2.1
43.0
|
L
 -62.2%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
9.4
|
0.2
|
L
 -4.2%
H
0.2
0.2
|
L
 -8%
H
0.2
0.3
|
L
 -64.1%
H
0.2
0.8
|
L
 -61.7%
H
0.2
0.8
|
L
 -90.9%
H
0.2
5.1
|
L
 -87.6%
H
0.2
24.7
|
L
 -99.7%
H
0.2
97.8
|
L
 -99.8%
H
0.2
140.7
|
| Voyager Therapeutics Inc |
|
187.3
|
3.1
|
L
 -1.3%
H
3.1
3.1
|
L
 -3.1%
H
3.0
3.2
|
L
 -16.7%
H
3.0
3.9
|
L
 -25.1%
H
3.0
4.5
|
L
 -1.9%
H
2.9
5.6
|
L
 -66.7%
H
2.6
11.7
|
L
 -6.1%
H
2.5
14.3
|
L
 -77.6%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
500.4
|
4.9
|
L
 -0.6%
H
4.9
5.0
|
L
 -4.3%
H
4.8
5.2
|
L
 -8.4%
H
4.8
5.5
|
L
 -6.7%
H
4.8
6.7
|
L
 -21.4%
H
4.8
12.3
|
L
 -67.8%
H
3.6
15.4
|
L
 -82.0%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
1,104.4
|
5.7
|
L
 -0.9%
H
5.7
5.8
|
L
 -2.9%
H
5.5
6.0
|
L
 -7.0%
H
5.5
6.5
|
L
 -22.2%
H
5.4
7.6
|
L
 -27.6%
H
5.0
21.7
|
L
 34.7%
H
3.5
21.7
|
L
 -11.1%
H
1.2
21.7
|
L
 -72.8%
H
1.2
56
|
| XBiotech Inc |
|
69.2
|
2.3
|
L
 1.3%
H
2.2
2.3
|
L
 -0.9%
H
2.2
2.3
|
L
 -1.7%
H
2.2
2.4
|
L
 -10.3%
H
2.2
2.7
|
L
 -26.3%
H
2.1
3.6
|
L
 -59.0%
H
2.1
10.0
|
L
 -85.7%
H
2.1
16.6
|
L
 -85.7%
H
2.1
26.4
|
| Exicure Inc |
|
11.2
|
1.8
|
L
 -8.8%
H
1.7
1.9
|
L
 8.6%
H
1.4
2.0
|
L
 -35.8%
H
1.4
3.0
|
L
 -51.7%
H
1.4
3.7
|
L
 -77.9%
H
1.4
9.5
|
L
 -67.4%
H
0.3
36
|
L
 -99.2%
H
0.3
297
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,446.7
|
8.4
|
L
 -4.6%
H
8.3
8.8
|
L
 -3.7%
H
8.3
9
|
L
 21.5%
H
6.9
9.0
|
L
 38.7%
H
5.8
9.0
|
L
 63.7%
H
4.9
10.1
|
L
 228.6%
H
1.5
10.1
|
L
 138.1%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
349.0
|
3.7
|
L
 0.3%
H
3.6
3.8
|
L
 -5.1%
H
3.6
3.9
|
L
 -10.2%
H
3.6
4.7
|
L
 -16.3%
H
3.6
4.7
|
L
 148.3%
H
1.4
4.8
|
L
 103.3%
H
0.2
6.6
|
L
 -35.4%
H
0.2
6.6
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,446.5
|
19.5
|
L
 -4.6%
H
18.8
20.6
|
L
 30.2%
H
14.4
21.3
|
L
 39.3%
H
13.9
21.3
|
L
 51.8%
H
10.4
21.3
|
L
 112.1%
H
6.9
21.3
|
L
 -21.3%
H
6.9
27.2
|
L
 -39.7%
H
6.9
43.6
|
L
 6.3%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.5
|
4.3
|
L
 -5.5%
H
4.2
4.4
|
L
 -1.8%
H
4.1
4.6
|
L
 -5.1%
H
3.7
5.0
|
L
 107.8%
H
0.3
7.3
|
L
 -90.7%
H
0.3
59.0
|
L
 -100.0%
H
0.3
2973348
|
L
 -100.0%
H
0.3
46612260
|
L
 -100.0%
H
0.3
67850460
|
| Zentalis Pharma Inc |
|
320.3
|
4.5
|
L
 -10.2%
H
4.3
5.1
|
L
 -5.9%
H
4.3
5.6
|
L
 22.6%
H
3.6
5.6
|
L
 17.2%
H
3.4
5.6
|
L
 214.7%
H
1.2
7.0
|
L
 -82.8%
H
1.0
29.0
|
L
 -90.9%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
513.0
|
5.4
|
L
 -4.9%
H
5.4
5.7
|
L
 0.2%
H
5.1
5.7
|
L
 27.7%
H
4.1
6.0
|
L
 -5.1%
H
3.3
6.0
|
L
 221.4%
H
1.3
7.4
|
L
 -20.9%
H
1.0
7.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,314.9
|
20.5
|
L
 0.1%
H
20.5
20.9
|
L
 0.3%
H
19.6
20.9
|
L
 10.9%
H
17.2
20.9
|
L
 -10.4%
H
16.3
23.1
|
L
 -44.6%
H
16.0
41.2
|
L
 -30.8%
H
13.5
44.3
|
L
 -87.3%
H
13.5
160.2
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
10,140.0
|
134.1
|
L
 -0.1%
H
134.0
134.4
|
L
 -0.2%
H
133.9
134.4
|
L
 1.2%
H
132.5
134.4
|
L
 47.9%
H
75
134.4
|
L
 238.6%
H
34.3
134.4
|
L
 557.3%
H
14.2
134.4
|
L
H
14.2
134.4
|
L
H
14.2
134.4
|
| Intensity Therapeutics Inc |
|
11.9
|
4.4
|
L
 -0.2%
H
4.4
4.5
|
L
 -9.3%
H
4.4
4.9
|
L
 11.4%
H
3.8
5
|
L
 -16.1%
H
3.5
5.4
|
L
 -42.8%
H
3.5
43.5
|
L
 -95.6%
H
3.5
286
|
L
 -95.6%
H
3.5
286
|
L
 -95.6%
H
3.5
286
|
| Renovaro Biosciences Inc |
|
11.8
|
2.6
|
L
 -5.4%
H
2.6
2.8
|
L
 -12.4%
H
2.6
3.1
|
L
 -37.1%
H
2.6
4.8
|
L
 0.4%
H
1.8
5.0
|
L
 -89.4%
H
1.2
28
|
L
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
41.1
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 -3.1%
H
0.9
1
|
L
 -7%
H
0.9
1.1
|
L
 -19.1%
H
0.9
1.3
|
L
 -55.7%
H
0.5
2.4
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Dianthus Therapeutics Inc |
|
5,617.5
|
102.8
|
L
 -2.8%
H
102.4
106.6
|
L
 2.9%
H
91.0
108.0
|
L
 17.6%
H
84.6
108.0
|
L
 12.6%
H
68.9
108.0
|
L
 395.5%
H
18.1
108.0
|
L
 13421.1%
H
6.6
108.0
|
L
 13421.1%
H
6.6
108.0
|
L
 13421.1%
H
6.6
108.0
|
| Incannex Healthcare Ltd (ADR) |
|
37.3
|
3.1
|
L
 -2.8%
H
3.1
3.2
|
L
 -3.4%
H
3.1
3.3
|
L
 -4%
H
3.1
4.0
|
L
 -23.7%
H
2.8
5
|
L
 -87.6%
H
2.5
49.8
|
L
 -98.1%
H
2.4
160.2
|
L
 -98.1%
H
2.4
160.2
|
L
 -98.1%
H
2.4
160.2
|
| Canton Strategic Holdings Inc |
|
161.2
|
2.1
|
L
 -3.2%
H
2.1
2.2
|
L
 -12.6%
H
2
2.4
|
L
 -34.9%
H
2
3.3
|
L
 -41.1%
H
2
3.9
|
L
 29.0%
H
1.1
9.1
|
L
 -98.6%
H
0.3
146.3
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Estrella Biopharma Inc |
|
32.7
|
0.8
|
L
 -5%
H
0.8
0.8
|
L
 -1.3%
H
0.7
0.9
|
L
 -18.3%
H
0.7
1.1
|
L
 -57.8%
H
0.7
1.8
|
L
 -12.6%
H
0.7
3.2
|
L
 -94.0%
H
0.6
15.5
|
L
 -94.0%
H
0.6
15.5
|
L
 -94.0%
H
0.6
15.5
|
| Lexeo Therapeutics Inc |
|
382.4
|
4.9
|
L
 4.5%
H
4.6
5.0
|
L
 2.7%
H
4.4
5.0
|
L
 -3.4%
H
4.3
5.4
|
L
 -23.1%
H
4.0
6.4
|
L
 25.2%
H
3.6
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Cartesian Therapeutics Inc |
|
238.9
|
8.1
|
L
H
8.0
8.3
|
L
 -6.3%
H
7.9
8.7
|
L
 -18.3%
H
7.9
11
|
L
 18%
H
5.8
11
|
L
 -33.3%
H
5.6
14.6
|
L
 -99.2%
H
5.6
1278
|
L
 -99.7%
H
5.6
4230
|
L
 -99.9%
H
5.6
25199.6
|
| Elevai Labs Inc |
|
4.6
|
1.0
|
L
 -2.9%
H
1.0
1.0
|
L
 -5.6%
H
1
1.1
|
L
 -24.4%
H
1
1.6
|
L
 -67.2%
H
1
3.2
|
L
 -99.5%
H
1
309.1
|
L
H
1
499117.9
|
L
H
1
499117.9
|
L
H
1
499117.9
|
| Neurogene Inc |
|
720.4
|
36.1
|
L
 -1.6%
H
34.7
36.7
|
L
 -8.5%
H
34.7
39.6
|
L
 12.0%
H
29.7
43.7
|
L
 32.4%
H
24.9
43.7
|
L
 64.6%
H
15.9
43.7
|
L
 154.7%
H
6.9
74.5
|
L
 154.7%
H
6.9
74.5
|
L
 154.7%
H
6.9
74.5
|
| Cg Oncology Inc |
|
6,113.3
|
69.3
|
L
 -3.4%
H
69.1
71.9
|
L
 -5.1%
H
68.5
73.6
|
L
 4.6%
H
63.8
77
|
L
 -0.8%
H
53.2
77
|
L
 166.5%
H
23.7
77
|
L
H
14.8
77
|
L
H
14.8
77
|
L
H
14.8
77
|
| FibroBiologics Inc |
|
4.5
|
0.7
|
L
 -3.9%
H
0.7
0.8
|
L
 -11.9%
H
0.7
0.9
|
L
 -8.6%
H
0.7
1.0
|
L
 -52.6%
H
0.7
1.5
|
L
 -94.5%
H
0.7
14.4
|
L
H
0.7
1100
|
L
H
0.7
1100
|
L
H
0.7
1100
|
| Alto Neuroscience Inc |
|
1,058.4
|
27.2
|
L
 0.6%
H
26
27.6
|
L
 -2.1%
H
25.7
28.8
|
L
 18.8%
H
22.3
28.9
|
L
 0.3%
H
17.9
28.9
|
L
 872.5%
H
2.9
28.9
|
L
H
1.6
28.9
|
L
H
1.6
28.9
|
L
H
1.6
28.9
|
| Fractyl Health Inc |
|
120.6
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -16.5%
H
0.8
0.9
|
L
 -12.6%
H
0.7
1.0
|
L
 28.8%
H
0.6
1.0
|
L
 -59.1%
H
0.4
2.4
|
L
H
0.4
15
|
L
H
0.4
15
|
L
H
0.4
15
|
| Kyverna Therapeutics Inc |
|
449.9
|
7.4
|
L
 -1.1%
H
7.3
7.5
|
L
 -4.9%
H
7.2
7.8
|
L
 -10.8%
H
7.2
10.3
|
L
 -27.7%
H
7.2
11.2
|
L
 80.5%
H
2.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
46.7
|
1.2
|
L
 1.6%
H
1.2
1.3
|
L
 -3.9%
H
1.2
1.3
|
L
 4.2%
H
1.2
1.4
|
L
 -16.2%
H
1.1
1.5
|
L
 -46.8%
H
1.1
4.0
|
L
H
1.1
15
|
L
H
1.1
15
|
L
H
1.1
15
|
| NeOnc Tech Holdings Inc |
|
95.2
|
3.7
|
L
 8.9%
H
3.4
3.9
|
L
 3.7%
H
3
3.9
|
L
 -28.2%
H
3
5.2
|
L
 -25.9%
H
3
6.8
|
L
 -24.2%
H
3
13.0
|
L
H
3
13.0
|
L
H
3
13.0
|
L
H
3
13.0
|
| LENZ Therapeutics Inc |
|
167.4
|
5.3
|
L
 3.5%
H
5.1
5.4
|
L
 7.0%
H
4.7
5.4
|
L
 -8.3%
H
4.7
6.2
|
L
 -46.6%
H
4.7
10.6
|
L
 -83.8%
H
4.7
50.4
|
L
 -78.6%
H
4.7
50.4
|
L
 -78.6%
H
4.7
50.4
|
L
 -78.6%
H
4.7
50.4
|
| Boundless Bio Inc |
|
56.6
|
2.5
|
L
 1.6%
H
2.5
2.6
|
L
 2.0%
H
2.4
2.6
|
L
 80%
H
2.3
2.8
|
L
 62.6%
H
1.4
2.8
|
L
 111.8%
H
1.0
2.8
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
550.7
|
14.7
|
L
 6.0%
H
13.7
15.1
|
L
 0.7%
H
13.4
15.1
|
L
 26.8%
H
11.4
16.9
|
L
 13.7%
H
11.2
16.9
|
L
 184.4%
H
5.1
16.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
419.4
|
6.4
|
L
 0.6%
H
6.4
6.8
|
L
 -1.5%
H
6.1
6.8
|
L
 -3.3%
H
5.8
7.1
|
L
 -9.1%
H
5.6
8.1
|
L
 25.2%
H
5.0
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
24.0
|
3.4
|
L
 -3.4%
H
3.3
3.6
|
L
 -15.6%
H
3.2
4.1
|
L
 -29.6%
H
3.2
5.1
|
L
 45.5%
H
2.1
6.9
|
L
 131.1%
H
1.1
6.9
|
L
 -59.0%
H
0.6
9.5
|
L
 -59.0%
H
0.6
9.5
|
L
 -59.0%
H
0.6
9.5
|
| Inhibrx Biosciences Inc |
|
1,260.5
|
85.9
|
L
 -1.9%
H
85.3
87.5
|
L
 -5.8%
H
83.2
91.5
|
L
 -7.9%
H
83.2
106.4
|
L
 -25.4%
H
83.2
151.0
|
L
 275.9%
H
20.6
155.3
|
L
 596.8%
H
12.2
155.3
|
L
 596.8%
H
12.2
155.3
|
L
 596.8%
H
12.2
155.3
|
| Rapport Therapeutics Inc |
|
1,976.7
|
41.3
|
L
 -2.9%
H
41.0
43
|
L
 3.5%
H
38.6
44.3
|
L
 8.2%
H
37.1
44.3
|
L
 12.4%
H
32.4
44.3
|
L
 171.9%
H
13.6
44.3
|
L
H
6.4
44.3
|
L
H
6.4
44.3
|
L
H
6.4
44.3
|
| Artiva Biotherapeutics Inc |
|
486.9
|
10.0
|
L
 0.2%
H
9.6
10.3
|
L
 1.0%
H
8.8
10.3
|
L
 7.1%
H
8.5
10.3
|
L
 -14.6%
H
6.6
13
|
L
 288.4%
H
2.2
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
2,774.9
|
58.3
|
L
 -3.3%
H
57.2
60.6
|
L
 -3.9%
H
55.4
63.8
|
L
 32.8%
H
42.0
66.6
|
L
 73.6%
H
27.6
66.6
|
L
 398.3%
H
9.6
66.6
|
L
H
4.8
66.6
|
L
H
4.8
66.6
|
L
H
4.8
66.6
|
| BioAge Labs Inc |
|
975.3
|
21.9
|
L
 -3.1%
H
21.8
22.7
|
L
 -3.4%
H
21.4
23.8
|
L
 2.2%
H
20.6
26.0
|
L
 19.5%
H
14.7
26.0
|
L
 360.9%
H
4.1
26.0
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| Voyager Acq Corp (Class A) |
|
64.8
|
2.1
|
L
 -2.4%
H
2.0
2.2
|
L
 -3.3%
H
2.0
2.3
|
L
 -50.5%
H
1.7
3.9
|
L
 -84.0%
H
1.7
27.4
|
L
 -80.3%
H
1.7
27.4
|
L
H
1.7
27.4
|
L
H
1.7
27.4
|
L
H
1.7
27.4
|
| OnKure Therapeutics Inc (Class A) |
|
174.5
|
4.3
|
L
 3.6%
H
4.1
4.4
|
L
 2.6%
H
3.9
4.4
|
L
 -2.7%
H
3.9
4.8
|
L
 -13.8%
H
2.9
5.4
|
L
 92.9%
H
1.9
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
3.1
|
L
 -2.5%
H
3.1
3.2
|
L
 -26.1%
H
3
4.3
|
L
 -26.0%
H
3
4.7
|
L
 -31.8%
H
3
5.3
|
L
 86.2%
H
1.3
7.8
|
L
 35.2%
H
1.3
7.8
|
L
 35.2%
H
1.3
7.8
|
L
 35.2%
H
1.3
7.8
|
| Upstream Bio Inc |
|
358.6
|
6.6
|
L
 -5.6%
H
6.5
7.0
|
L
 -9.4%
H
6.5
7.3
|
L
 4.6%
H
6.2
8
|
L
 -31.6%
H
5.9
9.7
|
L
 -38.7%
H
5.9
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Septerna Inc |
|
1,541.6
|
34.2
|
L
 1.5%
H
32.7
34.5
|
L
 0.4%
H
30.6
35.1
|
L
 -1.9%
H
30.6
38.0
|
L
 32.3%
H
22.8
38.0
|
L
 174.3%
H
10.6
38.0
|
L
H
4.2
38.0
|
L
H
4.2
38.0
|
L
H
4.2
38.0
|
| Polyrizon Ltd |
|
30.0
|
14.4
|
L
 6.7%
H
13.4
14.7
|
L
 10.1%
H
12.2
14.7
|
L
 9.1%
H
11.1
15.9
|
L
 -1.7%
H
10.4
18.0
|
L
 65.4%
H
2.9
18.2
|
L
H
2.9
7200
|
L
H
2.9
7200
|
L
H
2.9
7200
|
| Medicus Pharma Ltd |
|
21.5
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 8.6%
H
0.4
0.4
|
L
 -15.6%
H
0.3
0.5
|
L
 11.8%
H
0.3
0.5
|
L
 -87.7%
H
0.3
3.1
|
L
 -94.4%
H
0.3
8.9
|
L
 -94.4%
H
0.3
8.9
|
L
 -94.4%
H
0.3
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,496.2
|
10.3
|
L
 -5.5%
H
10.3
10.6
|
L
 -8.6%
H
10.2
11.1
|
L
 3.2%
H
10.0
12.2
|
L
 -0.1%
H
8.7
12.2
|
L
 -36.6%
H
6.3
14.8
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
2,039.3
|
142.2
|
L
 -1.2%
H
139.0
143.6
|
L
 -6.4%
H
120.6
158.1
|
L
 19.6%
H
116.8
161.4
|
L
 8.8%
H
100
161.4
|
L
 294.9%
H
34.6
161.4
|
L
 945.4%
H
11.2
161.4
|
L
 945.4%
H
11.2
161.4
|
L
 945.4%
H
11.2
161.4
|
| Zhengye biotech Holding Ltd |
|
65.4
|
1.4
|
L
 -51.6%
H
1.3
2.3
|
L
 84%
H
0.7
8.0
|
L
 91.7%
H
0.6
8.0
|
L
 50%
H
0.6
8.0
|
L
 -74.8%
H
0.6
13.1
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
| Sionna Therapeutics Inc |
|
2,033.1
|
45.0
|
L
 -4.6%
H
44.2
47.7
|
L
 1.5%
H
43.1
51.6
|
L
 16.0%
H
37.3
51.6
|
L
 4.2%
H
32.3
51.6
|
L
 136.8%
H
16.4
51.6
|
L
H
7.3
51.6
|
L
H
7.3
51.6
|
L
H
7.3
51.6
|
| Zenas Biopharma Inc |
|
1,988.1
|
31.5
|
L
 -2.7%
H
31.0
32.4
|
L
 7.1%
H
27.5
34.1
|
L
 51.4%
H
20.1
34.1
|
L
 56.9%
H
16.4
34.1
|
L
 120.1%
H
13.5
44.6
|
L
 200.8%
H
8.9
44.6
|
L
 200.8%
H
8.9
44.6
|
L
 200.8%
H
8.9
44.6
|
| Advanced Biomed Inc |
|
20.2
|
12.3
|
L
 73.0%
H
8.1
18.7
|
L
 135.6%
H
4.9
18.7
|
L
 136.9%
H
4.1
18.7
|
L
 129.4%
H
3.7
18.7
|
L
 -3.9%
H
3.6
18.7
|
L
H
3.6
82
|
L
H
3.6
82
|
L
H
3.6
82
|
| Caris Life Sciences Inc (Class A) |
|
4,347.6
|
15.4
|
L
 -2.2%
H
15.3
15.8
|
L
 -11.9%
H
15.1
17.9
|
L
 -11.2%
H
15.1
20.0
|
L
 -25.0%
H
14.2
20.7
|
L
 -49.2%
H
14.2
42.5
|
L
 -45.1%
H
14.2
42.5
|
L
 -45.1%
H
14.2
42.5
|
L
 -45.1%
H
14.2
42.5
|
| Propanc Biopharma Inc |
|
3.3
|
1.4
|
L
 4.4%
H
1.4
1.5
|
L
 -11.7%
H
1.3
1.7
|
L
 -2.7%
H
1.3
2.5
|
L
 -50%
H
1.3
6.8
|
L
 -98.0%
H
1.3
234
|
L
 -98.0%
H
1.3
234
|
L
 -98.0%
H
1.3
234
|
L
 -98.0%
H
1.3
234
|
| SpyGlass Pharma Inc |
|
686.7
|
20.5
|
L
 1.3%
H
20.0
20.8
|
L
 -0.3%
H
19.6
21.9
|
L
 6.2%
H
18.6
22.9
|
L
 -16.1%
H
17.1
25.8
|
L
 -22.2%
H
17.1
30.6
|
L
 -22.2%
H
17.1
30.6
|
L
 -22.2%
H
17.1
30.6
|
L
 -22.2%
H
17.1
30.6
|
| AgomAb Therapeutics NV ADR |
|
571.3
|
11.6
|
L
 -0.3%
H
11.2
11.8
|
L
 -8.2%
H
11.2
13.0
|
L
 -2.0%
H
11.2
17.8
|
L
 10.0%
H
8.8
17.8
|
L
 -20.8%
H
8.8
17.8
|
L
 -20.8%
H
8.8
17.8
|
L
 -20.8%
H
8.8
17.8
|
L
 -20.8%
H
8.8
17.8
|
| Generate Biomedicines Inc |
|
1,781.9
|
13.9
|
L
 -3.4%
H
13.9
14.4
|
L
 -1.2%
H
13.2
14.6
|
L
 -12.5%
H
13.2
18.2
|
L
 6.7%
H
11.9
18.2
|
L
 9.9%
H
11
18.2
|
L
 9.9%
H
11
18.2
|
L
 9.9%
H
11
18.2
|
L
 9.9%
H
11
18.2
|
| Atrium Therapeutics Inc |
|
208.2
|
12.2
|
L
 -1.0%
H
12.1
12.4
|
L
 -1.1%
H
11.6
12.4
|
L
 -6.0%
H
11.6
13.8
|
L
 -10.9%
H
11.4
14.8
|
L
 -17.5%
H
11.4
16.8
|
L
 -17.5%
H
11.4
16.8
|
L
 -17.5%
H
11.4
16.8
|
L
 -17.5%
H
11.4
16.8
|
| Jatt II Acquisition Corp |
|
-
|
11.0
|
L
H
11.0
11.0
|
L
 2.8%
H
10.6
11.5
|
L
 1.9%
H
10.3
12.6
|
L
 3.9%
H
10
12.6
|
L
 4.3%
H
10
12.6
|
L
 4.3%
H
10
12.6
|
L
 4.3%
H
10
12.6
|
L
 4.3%
H
10
12.6
|
| Kailera Therapeutics Inc |
|
2,305.0
|
17.8
|
L
 -3.4%
H
17.7
18.8
|
L
 -7.8%
H
17.5
19.7
|
L
 -22.3%
H
17.5
23.8
|
L
 -26.8%
H
17.5
25.7
|
L
 -31.6%
H
17.5
28.2
|
L
 -31.6%
H
17.5
28.2
|
L
 -31.6%
H
17.5
28.2
|
L
 -31.6%
H
17.5
28.2
|
| Alamar Biosciences Inc |
|
1,741.1
|
25.1
|
L
 -0.1%
H
24.0
25.4
|
L
 -3.9%
H
23.5
27.3
|
L
 10.3%
H
21.8
29.4
|
L
 3.5%
H
18.8
29.4
|
L
 14.2%
H
18.8
29.4
|
L
 14.2%
H
18.8
29.4
|
L
 14.2%
H
18.8
29.4
|
L
 14.2%
H
18.8
29.4
|
| LakewoodAmedex |
|
6.0
|
3.4
|
L
 83.3%
H
3
6.9
|
L
 40.3%
H
1.7
6.9
|
L
 -6.6%
H
1.7
6.9
|
L
 -96.1%
H
1.7
94
|
L
 -96.1%
H
1.7
94
|
L
 -96.1%
H
1.7
94
|
L
 -96.1%
H
1.7
94
|
L
 -96.1%
H
1.7
94
|
| Hemab Therapeutics Holdings |
|
2,299.3
|
49.2
|
L
 2.0%
H
47.3
49.4
|
L
 13.6%
H
42.8
52.1
|
L
 55.1%
H
27.5
52.1
|
L
 44.8%
H
23
52.1
|
L
 44.8%
H
23
52.1
|
L
 44.8%
H
23
52.1
|
L
 44.8%
H
23
52.1
|
L
 44.8%
H
23
52.1
|
| Odyssey Therapeutics Inc |
|
893.9
|
18.6
|
L
 2.1%
H
17.4
18.9
|
L
 7.9%
H
16.6
18.9
|
L
 -0.6%
H
15.1
19.6
|
L
 13.3%
H
15.1
20
|
L
 13.3%
H
15.1
20
|
L
 13.3%
H
15.1
20
|
L
 13.3%
H
15.1
20
|
L
 13.3%
H
15.1
20
|
| Lakefront Biotherapeutics NV |
|
1,884.6
|
28.8
|
L
 -1.5%
H
28.8
29.3
|
L
 -2.4%
H
28.8
30.2
|
L
 -0.6%
H
28.7
30.9
|
L
 0.7%
H
26.4
30.9
|
L
 0.7%
H
26.4
30.9
|
L
 0.7%
H
26.4
30.9
|
L
 0.7%
H
26.4
30.9
|
L
 0.7%
H
26.4
30.9
|
| Conexeu Sciences Inc |
|
249.9
|
9.3
|
L
 -3.2%
H
9.1
10
|
L
 -16.5%
H
8.6
11.4
|
L
 -23.3%
H
8.1
13.7
|
L
 -28.5%
H
8.1
18.8
|
L
 -28.5%
H
8.1
18.8
|
L
 -28.5%
H
8.1
18.8
|
L
 -28.5%
H
8.1
18.8
|
L
 -28.5%
H
8.1
18.8
|
| Veraxa Biotech AG |
|
289.9
|
2.1
|
L
 -2.4%
H
2.0
2.2
|
L
 -3.3%
H
2.0
2.3
|
L
 -50.5%
H
1.7
3.9
|
L
 -91.7%
H
1.7
26.0
|
L
 -91.7%
H
1.7
26.0
|
L
 -91.7%
H
1.7
26.0
|
L
 -91.7%
H
1.7
26.0
|
L
 -91.7%
H
1.7
26.0
|
| Kardigan Inc |
|
2,042.3
|
22.9
|
L
 -0.2%
H
22.3
24.8
|
L
 4.0%
H
19.8
24.8
|
L
 0.4%
H
19.8
27
|
L
 3.9%
H
19.8
27
|
L
 3.9%
H
19.8
27
|
L
 3.9%
H
19.8
27
|
L
 3.9%
H
19.8
27
|
L
 3.9%
H
19.8
27
|